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LAY ABSTRACT
Cancer is where cells in the body grow in an uncontrolled manner and can potentially
spread and take over the normal cells. My dissertation covers Acute Myeloid Leukemia (AML),
a type of blood cancer. It is the most common type of leukemia cancer while also having the
poorest survival rates (21450 cases and 10920 deaths per year in the United States). Treatment
has been relatively unchanged from the 1970’s until 2017. Even with the new treatment
approvals in 2017 and 2018, survival improvements have been modest at best. New treatments
are urgently needed to improve long term survival of patients with AML.
My research focuses on apoptosis, also known as programed cell death. This is a way a
cell chooses to kill itself. Normal cells die if they get damaged or abnormal. Cancer cells survive
when they are able to avoid this. As cancer cells are more abnormal and stressed than normal
cells, cancer cells need to avoid cell death more so than normal cells. Inducing apoptosis can
preferentially kill cancer cells over normal cells. The goal of any cancer treatment is to kill as
many cancer cells and as few normal cells as possible.
Venetoclax is a drug that targets a protein called Bcl-2, which prevents apoptosis. The
drug works well in the lab and the clinic but resistance to the drug quickly occurs. Our lab and
others found that a second protein called Mcl-1, which is related to Bcl-2, causes this resistance.
In chapter 2, using lab tools, I show that direct targeting of Mcl-1 overcomes resistance to
venetoclax. In chapters 3 and 4, I show that using drugs that both target blood cancer cells and
decrease Mcl-1 can enhance venetoclax treatment. In chapter 5, I discuss the future directions
and implications of the research.
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CHAPTER 1: INTRODUCTION
1.1 Clinical Pathology of Acute Myeloid Leukemia
1.1.1 Normal hematopoiesis
In healthy individuals, the production of blood is tightly controlled by the process of
hematopoiesis (from the Greek “haima” for “blood” and “poiein” “to make”) as the
hematopoietic stem cell (HSC) differentiates into the various blood cell progenitors and
differentiated blood cells in a hierarchical manner (Figure 1.1) (1). Turnover is constant for most
blood cells (except for a few long lived immune cells), which requires constant replenishment of
these cell components (2). With only 10,000 to 20,000 HSCs and over 1011 cells that need to be
made each day; this process requires coordination and delegation (3). The multipotent HSCs
undergo symmetric division to replenish the stem cell (SC) pool and asymmetric division to
generate committed progenitor cells. The HSCs divide more slowly than committed progenitors
and as a result acquire fewer mutations than other cancer types (4).
These HSCs generate intermediate cells that have limited self-renewal, which in turn
generate the terminal blood cells (e.g. red blood cells [erythrocytes, RBCs], thrombocytes
[platelets], plasma cells) (2). The lymphoid lineage is derived from the common lymphoid
progenitor and plays a critical role in the generation of natural killer (NK) cells, B cells
(including plasma cells), and T cells. The myeloid lineage is derived from the common myeloid
lineage and plays an important role in the generation of RBCs, platelets, and other blood cell
types. The extent to which cells are produced in the various lineages is dependent on the various
supportive signals which balance the number of cells. For example, in higher elevation or
anemia, more blood cells are needed. Erythropoietin is secreted by the kidney to increase red
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blood cell (RBC) production. Dysregulation in these hierarchical processes can lead to disease.
Too many platelets can lead to excess clotting of the blood. Too few platelets or RBCs can lead
to excessive bleeding and anemia, respectively. Too many or too few immune cells can lead to
autoimmune disorders or a weakened ability to fight infections. Regulation of hematopoiesis is
critical for homeostasis.

Figure 1.1 Diagram of hematopoiesis. (From Wikimedia Commons by Mikael Häggström
et.al.)

1.1.2 Epidemiology and prognosis of leukemia
Leukemia is a blood disorder that is the result of arrested differentiation and uncontrolled
proliferation of the blood progenitor cells (2). When a clonal population dominates, the other
types of cells produced by hematopoiesis are diminished. The term leukemia comes from the
observation of patients with excess white blood cells and the Greek words “leukos” which means
white and “haima” which means blood. The white blood cell clonal population had overtaken
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and crowded out the other blood types, which created blood that was milky in appearance. The
result of this clonal dominance is anemia, a weakened immune system, excess bleeding, and
other associated symptoms from lacking the critical types of blood cells.
This clonal nature of leukemia was determined by researchers looking at the
chromosomal status of patients. Early studies focused on chromosomal changes for females, as
one parental X chromosome is randomly inactivated in each cell (5). Leukemia, being a clonal
disease, leads to a disproportionate amount of one allele being activated over the other as the
blood cells are disproportionately derived from a single clone. This was demonstrated by the Xlinked gene G6PD [glucose-6-phosphate dehydrogenase] in heterozygous women where one
allele had a near complete dominance, providing early proof of the clonal nature of leukemia and
cancer in general (6, 7).
Leukemias are also classified by their differentiation and their cell lineage (8). Acute
leukemias (common in pediatric cancer) are the result of the uncontrolled proliferation of
immature blood cells with a more rapid onset, while chronic leukemias (very rare in children) are
a result of the uncontrolled proliferation of more mature blood cells. Acute leukemias will kill
the patient in weeks to months if left untreated, while chronic leukemias will kill the patients in
years if left untreated (8). Lymphoblastic leukemias are a disorder of the common lymphoid
progenitor lineage which normally produces natural killer cells, T cells, and B cells, while
myeloid leukemias are a disorder of the common myeloid progenitor lineage which normally
produces thrombocytes, erythrocytes, mast cells, basophils, neutrophils, eosinophils,
macrophages, and dendritic cells. The four main subtypes of leukemia are distinguished by these
two pairs of criteria; acute lymphoblastic leukemia (ALL, more common in children), acute
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myeloid leukemia (AML, found in children but more common in adults), chronic lymphoblastic
leukemia (CLL), and chronic myeloid leukemia (CML).
AML is the most common form of acute leukemia in the United States with 21,450 cases
expected in 2019 (9). Compared to other leukemia subtypes, AML has by far the most deaths
(10,920 projected for 2019) and the poorest survival (9). 5 year survival is 67% for those 19 and
under and 24% for those 20 and older with the prognosis declining with age (10). A further
challenge is the 68 year median age of onset, which means treating older patients with
comorbidities (11). Many patients are unable to tolerate standard chemotherapy and bone
marrow transplant, leading to mortality and poor outcomes (12, 13). Only 40% of those above 65
years old are treated with chemotherapy within 3 months of diagnosis (14). For treated patients
over untreated patients, outcomes remain poor (65-69 years old 10 versus 4 months, 70 to 74
years old 8 versus 3 months, 75-79 years old 6 versus 2 months) (15-17). Leukemic stem cells
(LSCs) and their evasion of therapy are believed to be responsible for relapse (18, 19). Similar to
other cancers as well as normal tissues, this LSC population maintains the overall bulk leukemia
and due to its less proliferative (quiescent) nature does not respond to anti-proliferative
chemotherapeutics agents (20-22). In summary, little has changed in the standard of care over the
last several decades leading to only modest improvements in patient outcomes compared to other
cancers and leukemia subtypes (23).

1.1.3 FAB and WHO Classification Systems
The first classification system for leukemia was developed by the French-AmericanBritish (FAB) co-operative group (24). The group independently and cooperatively looked at the
physical appearance of stained leukemia samples. The goal was to standardize leukemia subtypes
to better compare clinical trial data among different clinical trials and institutions, and reduce
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discrepancies in the classification of leukemia cases. The first distinction was between
lymphoblastic and myeloid leukemias. For the myeloid leukemias, six subtypes were defined
(M1-M6). Two additional subtypes, M0 for minimally differentiated AML and M7 for
megakaryoblastic leukemia (AMKL), were later added (25, 26). While an improvement, these
classifications were superficial and often non-specific to the functional properties of the
leukemias.
In a partial move from phenotypic to genotypic classification, the World Health
Organization (WHO) devised a system that includes genetic, treatment, and other causal
backgrounds for AML subtypes (Table 1.1, (27)). Some FAB subtypes, like APL (acute
promyelocytic leukemia, M3, all cases related to retinoic acid receptor alpha [RARA] fusions)
and AMKL (M7, some cases are due to down syndrome [DS]), are strongly correlated to genetic
alterations (28). Genetic alterations are able to predict the behavior of the disease and guide
treatment, including the use of targeted therapies, aggressive chemotherapy, and the value
proposition of a bone marrow transplant (BMT) (29). With the advent of biologic tools including
sequencing technologies, our ability to probe the genetic subtypes has exponentially grown. The
understanding of the different behavior of specific subtypes led to the re-classification of AML
subtypes in 2002 and later 2016 by the WHO (27, 28). As the study of AML progresses, the
classification of AML will move away from surface level appearances to functional and genetic
properties of the cancer that are more relevant for treatment decision making.
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World Health Organization (WHO) 2016 classification of acute myeloid leukemia and
related neoplasms
AML with recurrent genetic abnormalities


AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1



AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (M4eo)



APL with PML-RARA (M3)



AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A AML with t(6;9)(p23;q34.1); DEKNUP214



AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM



AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 Provisional entity



AML with BCR-ABL1 AML with mutated NPM1



AML with biallelic mutations of CEBPA Provisional entity



AML with mutated RUNX1

AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, Not otherwise specified


AML with minimal differentiation (M0)



AML without maturation (M1)



AML with maturation (M2)



Acute myelomonocytic leukemia (M4)



Acute monoblastic/monocytic leukemia(M5)



Pure erythroid leukemia (M6)



Acute megakaryoblastic leukemia(M7)



Acute basophilic leukemia (M8)



Acute panmyelosis with myelofibrosis

Myeloid sarcoma
Myeloid proliferations related to Down syndrome


Transient abnormal myelopoiesis

 Myeloid leukemia associated with Down syndrome
Table 1.1. World Health Organization (WHO) 2016 classification of acute myeloid
leukemia. (27)
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1.1.4 Genetics of AML
Biologically, AML is a very heterogeneous disease. AML has one of the lowest
mutational rates among cancer types and even the most common AML mutations appear less
than 30% of the time (4, 30). The mutations that do occur have broad acting functions, such as
signal transduction, transcription factors, differentiation, and epigenetic regulation (31). As a
result, the AML cells are difficult to distinguish, both by the host’s immune system, and by
targeted therapy.
AML has been theorized to be due to a “two-hit” model where mutations in one class of
genes provide a proliferative advantage and mutations in a second class of genes impair
differentiation (32). Both of these hits alone do not lead to leukemia. In combination, they lead to
cancerous blood, i.e. leukemia. As people age, HSCs can gain a proliferation advantage either by
chance (stochastic) or by driver mutations (e.g. DNMT3A, TET2, ASXL1) which confer a
proliferative advantage (31, 33). Over time, HSCs acquire mutations and clonal hematopoiesis of
indeterminate potential (clonal dominance, CHIP), increasing the risk of leukemia (34).
Myelodysplastic syndromes (MDS) occur when blood precursors fail to properly differentiate,
leading to a lack of differentiated blood products (35). Myeloproliferative neoplasms (MPN)
occur when excess proliferation causes pathology (35). Both MDS and MPN can lead to AML,
particularly in older adults. Patients with genetic predispositions (e.g. Li Fraumeni [TP53
mutation], Down syndrome [trisomy 21], Fanconi anemia or BRCA1/2 mutations [impaired DNA
repair]) may already have a “hit” or be prone to acquiring mutational “hits” (36-38). Regardless
of the genetic, environmental, or random cause, it is when both the lack of differentiation and
excess proliferation occur that leads to leukemia.
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These AML “hits” led to the classification of AML mutations into Class I Signal
Activation (which confers proliferation advantages, e.g. FLT3, NRAS, KRAS, c-Kit) and Class II
Transcription and Differentiation (which prevents differentiation and confers stemness, e.g.
RUNX1, CEBPA, NPM1) classes (39). A newer third class, Class III Epigenetic factors, has been
added (which affects general cellular programming, e.g. IDH1, IDH2, TET2, DMNT3A) (40).
Despite these categories being listed separately for clarity, AML alterations often overlap several
categories in their various roles (41).
A common theme of AML mutations is the synthesis of fusion proteins, which can occur
in any of these groups (also noted in the WHO classification of AML). APL (acute
promyelocytic leukemia) is the result of the PML-RARA fusion found in 13% of AML (often
excluded from AML statistics as a whole due to its unique treatment and good overall survival
rate) (42). The MLL gene (also known as KMT2A), has dozens of fusion partners such as AF6
(MLLT4), AF9 (MLLT3), AF10 (MLLT10), ELL, ENL (MLLT1), and partial tandem duplication
(PTD) being the most common partners (43). As a positive global regulator of transcription, the
pathways of these fusion proteins vary. MLL fusions are more common in infant acute leukemia
patients (70%) than adult leukemia patients (10%). MYH11-CBFB, present in 16% of AML, is
caused by either inv(16)(p13.1q22) or t(16;16)(p13.1;q22), results in blocked differentiation and
is one of the many alterations in AML that affects the CBF transcription complex (44, 45).
RUNX1-RUNX1T1, present in 7% of AML (mostly M2) and is caused by t(8;21)(q22;q22.1),
associates with CBF to alter transcription. BCR-ABL1 should be noted as unlike in CML where
it is more common, in AML it usually lacks IGH/VDJ and TARP regions, which means less
mutations and a more durable response to targeted inhibitors (46). Other fusion proteins (e.g.
RBM-MKL1) and non-fusion proteins (CEBPA whose loss of function leads to excess blasts)
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function in a similar transcriptional manner, maintaining the theme of hematopoiesis and its
dysregulation being a result of altered transcriptional control (47, 48).
Activation of proliferative signaling can help AML maintain a clonal advantage over
non-transformed cells. FLT3-ITD (inter tandem duplication) and FLT3-TKD (tyrosine kinase
domain

mutation)

activate

downstream

RAS/RAF/MEK/ERK

(proliferation)

and

PI3K/AKT/mTOR (survival) signaling pathways (49). NRAS (and occasionally KRAS) can also
be mutated as well as c-KIT (upstream of STAT3 and RAS) (50). Mutated PTPN11 (also known
as SHP2) is an oncogene whose loss of regulation over the RAS pathway leads to excess
proliferative signaling. Similar to the “two hit” model of leukemogenesis, these mutations often
co-occur with chromosomal abnormalities in hematopoietic transcription factors to gain both a
proliferative advantage while becoming more stem-like and resistant to cell death.
Tumor suppressor mutations can help AML maintain a proliferative advantage (41, 50).
TP53 mutations are common in most solid tumors but rare in AML cases (~8-10%). They are
more common in the elderly and provide the most dismal outcomes (51). WT1 is mutated in
~6% of AML and is a transcription factor which regulates proliferation and differentiation.
NPM1 is often mutated in ~20-25% of AML cases. In normal physiology, it is located in the
nucleus where it acts as a chaperone for tumor suppressor proteins like ARF and p53 in the DNA
damage response. It also plays a regulatory role in histone chaperoning, centrosome duplication,
ribosomal biogenesis, among its many roles. In aberrant cells, NPM1 is truncated and localizes
to the cytosol, losing these nuclear roles, taking the “brakes” off of the cell.
Similar to the partial role of tumor suppressors, the cohesin complex helps maintain
chromosomal integrity (52). The complex is responsible for the equal separation of sister
chromatids during anaphase. Disruptions in members of these complexes (e.g. STAG1/2,
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SMC1/3A, and Rad21) can lead to genetic instability that can lead to further gene mutations with
the potential to become oncogenic (53).
Epigenetic DNA methylation of histones can alter how open the chromatin structure is
with a more open structure leading to more transcription (41). DNMT3A is the most commonly
mutated member of this class (~20-28% of AML) and loss of function leads to impaired
differentiation (41). Epigenetic alterations are often mutually exclusive of each other as they
often share the same pathway (e.g. TET2, WT1, IDH1, and IDH2 in the WIT pathway). WT1,
IDH1/2, and TET1/2/3 are a part of the tumor suppressor WIT pathway (54). WT1 binds to the
DNA and recruits TET1/2/3 to help demethylate 5-methylcytosine (5mC), with TET2 being the
first of the three enzymes in this conversion changing 5mC to 5-hydroxymethylcytosine (5hmC).
Mutant WT1 does not bind to the DNA or TET2, halting enzymatic activity. Mutant TET2
prevents binding of TET2 to either WT1 or α-KG (alpha-ketoglutarate), preventing the
conversion of 5mC to 5hmC. IDH1/2 generates α-KG which binds and promotes TET2
enzymatic activity. This is disrupted by gain of function IDH1/2 mutants that generate the
oncometabolite 2-HG (alpha-hydroxyglutaric acid), which inhibits TET2 enzymatic activity.
Other chromatin remodelers often dysregulated in AML include ASXL1 (more common in the
elderly), EZH2, and KMD6A.
The spliceosome processes pre-mRNA, removing introns and sometimes exons (55).
Mutations in the spliceosome (e.g. SF3B1, SRSF2, U2AF1, and ZRSR2) can affect how RNA is
processed leading to alternatively spliced exons or non-functional proteins. This can affect many
downstream processes including chromatin structure, cell cycle control, and DNA repair. These
mutations are more common in older patients and are associated with mutations of chromatin
modifying genes (56).
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While age is a major risk factor in treatment, certain mutations of AML have worse
outcomes than others (57, 58). This may be due to the limited treatment options available and
may change as new targeted therapies become available and data is generated from the newly
approved AML therapies. The European Leukemia Net (ELN) generated an updated 2017 risk
stratification based on 1540 AML patients who were screened for 111 myeloid cancer genes and
chromosomal abnormalities (58). (Table 1.2) AML patients harboring TP53 mutations have by
far the worse prognosis. Half of AML cases are cytogenetically normal, having no chromosomal
abnormalities, while those with chromosomal loss or complex karyotypes (3 or more
chromosomal abnormalities) are at a higher risk. MDS and MPN can be considered as preleukemia as the cells are partly transformed. Knowing how aggressive the AML is can guide
treatment decisions. A more aggressive treatment (e.g. chemotherapy, hematopoietic stem cell
transplant [HSCT]) may be necessary to cure a high risk patient but would provide excess
toxicity in a lower risk patient. Alternatively, a higher risk patient may have a better quality of
life with non-curative treatment if curative treatment is unlikely to succeed.
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Risk Category

Status

Favorable

-t(8;21)(q22;q22.1); RUNX1-RUNX1T1
-inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11
-Mutated NPM1 without FLT3-ITD or with low allelic ratio (<0.5) of FLT3ITD
-Biallelic mutated CEBPA

Intermediate

-Mutated NPM1 and high allelic ratio (>0.5) of FLT3-ITD
-Wild-type NPM1 without FLT3-ITD or with low allelic ratio (<0.5) of FLT3ITD (without adverse-risk genetic lesions)
-t(9;11)(p21.3;q23.3); MLLT3-KMT2A
-Cytogenetic abnormalities not classified as favorable or adverse

Poor

-t(6;9)(p23;q34.1); DEK-NUP214
-t(v;11q23.3); KMT2A rearranged
-t(9;22)(q34.1;q11.2); BCR-ABL1
-inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM (EVI1)
-Monosomy 5 or del(5q); monosomy 7; monosomy 17/abn(17p)
-Complex karyotype, monosomal karyotype
-Wild-type NPM1 and high allelic ratio (>0.5) of FLT3-ITD
-Mutant RUNX1, ASXL1, or TP53
-Advanced age
-Poor performance Status
-Prior radiation or chemotherapy
-Prior MDS or MPN

Table 1.2. ELN risk stratification of molecular, genetic and cytogenetic alterations. (58)

13

1.1.5 Standard of Care
For the last several decades the standard of care in AML has been the “7 + 3” cytarabine
(ara-C) and daunorubicin regimen developed in 1973 (59). Four years later, bone marrow
transplant was found to cure some patients but many patients are unable to tolerate this intensive
regimen (60). The only advancements from 1977 until 2017 were the approval and removal of a
single drug (gemtuzumab ozogamicin known as GO), improvements in the use of standard
chemotherapy and bone marrow transplant, and the use of arsenic trioxide in 2000 and all-trans
retinoic acid in 2004 for APL (61-64). It should be noted that my dissertation research started in
early 2016 when considering past and future research directions (especially toward the
development of putative Mcl-1 inhibitors).
Older patients remain difficult to treat, as only 40% undergo chemotherapy within 3
months of diagnosis (14). (Note: the definition of older patients varies widely in AML and
cancer literature.) This is because curative treatment involves intense chemotherapy followed by
HSCT which also carries high risks. As patients age, the performance status worsens, leading to
more treatment related mortality. Despite these challenges, treatment outcomes have improved
from the 1970’s, with 5 year survival for those over 60 years of age improving from 8% with a
median of 1.8 months to 13% with a median of 11.5 months (65). Supportive care has made
HSCT more tolerable, even to patients in their 70’s (something unthinkable in years prior) (66).
Growth factors and transfusions help combat cytopenias (low blood cell counts of specific blood
cell types). Antibiotics and antifungals help patients with suppressed immune systems handle
pathogens. The outcome is grimmer as age increases, with 5 year survival for those over 75 years
of age remaining under 5%. In phase III trials of R/R (relapsed/refractory) AML of HDAC
(histone deacetylase) inhibitor or investigator choice, CR (complete response) rates of 12-18%
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were achieved with 3.3-6.3 month OS (overall survival) (67, 68). These patients may benefit
from less intensive, leukemic reduction regimens, but the goal of treatment is less curative and
more supportive. Outside of the relatively curable APL patients, new treatments are needed that
address the genetic foundation of AML and the frailty of the patients both from the disease and
advanced age.

Figure 1.2. Recent history of AML treatment and classification. A simplified timeline of the
recent history of AML. 7+3: cytarabine and daunorubicin, BMT: Bone marrow transplant, FAB:
French-American-British, WHO: World Health Organization, GO: gemtuzumab ozogamicin,
As2O3: Aresenic trioxide, ATRA: all-trans retinoic acid

1.1.6 Recent FDA Approvals
The decades of research into the genetic foundations of AML has finally paid off with the
approval of 4 new drugs in 2017 and another 4 new drugs in 2018 (timeline in Figure 1.2). Due
to the poor outcomes of older AML patients, the FDA (Food and Drug Administration) considers
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CR or CR with partial/incomplete hematological recovery (CRh) an acceptable outcome for
improving patient outcomes for those patients where the intent of therapy is not curative.
2017 started with the approval of a targeted therapy, the oral kinase inhibitor midostaurin
(trade name Rydapt, molecule name PKC412) for FLT3-mutated AML (69). FLT3 mutations are
associated with poor survival and are present in about ~30% of AML cases (30, 70, 71). The
FLT3 status (WT [wild type], ITD, TKD D835 or I836) is tested by the companion FDA
approved LeukoStrat CDx FLT3 Mutation Assay. The name PKC412 comes from initial studies
of its inhibition of Protein Kinase C (PKC). Midostaurin’s activity against mutated c-KIT led to
its approval for ASM, SM-AHN (systemic mastocytosis with associated hematologic neoplasm),
and MCL (mast cell leukemia) (72). Several other more specific FLT3 inhibitors are at various
stages of development with the broadly acting midostaurin being the first to gain FDA approval.
The FDA approval for AML was based on the Phase III clinical trial NCT00651261. 717 FLT3mutated patients from a pool of 3277 patients aged 18-59 received standard daunorubicin and
cytarabine induction and consolidation therapy. One of the randomized cohorts received 50 mg
BID (twice daily) midostaurin on days 8-21 of induction and consolidation and for an additional
12 months. The survival curves quickly separated but remained parallel, meaning there was
efficacy for induction therapy but not for maintenance therapy. The 4 years survival benefit was
51% vs 44% and CR in 59% vs 53% of patients in the midostaurin plus 7+3 and 7+3 arms,
respectively. 56% of patients had to interrupt dosing due to an adverse event and 21% had to
discontinue the drug entirely. 59% of patients were able to progress to allogenic HSCT. FLT3
has proven to be a viable target for AML but the outcome improvements are meager and may be
due to off target effects. Future FLT3 inhibitors and study of current generation drugs to use in
combination with FLT3 inhibitors will guide and potentially improve these treatments.
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A second targeted therapy, the oral IDH2 inhibitor enasidenib (trade name Idhifa,
molecule name AG-221) was approved for R/R AML with IDH2 mutations based on the single
arm phase I/II NCT01915498 trial (73). IDH2 mutations were tested by the RealTime IDH2
Assay to detect R140 and R172 mutations that are present in ~10% of adult AML cases (30). The
recommended dose based on dose escalation studies was 100 mg QD (daily) until disease
progression or unacceptable toxicity. 199 patients from 2 cohorts 19 to 100 years of age were
selected. 40% of patients responded to treatment and 23% of patients had CR/CRh with a median
duration of response (DOR) of 8.2 months. 34% of the patients became red blood cell (RBC) or
platelet transfusion independent. 43% of the patients had to interrupt dosing due to an adverse
event and 17% had to discontinue the drug entirely. For the patients who responded to the drug,
median survival was 9.3 months. Again, meager outcome improvements are promising for an
AML targeted therapy but treatment outcome improvements are urgently needed.
Mylotarg (also known as gemtuzumab ozogamicin) is an antibody drug conjugate
delivered by IV (intravenous) which was initially approved for CD33+ AML (85-90% of cases)
in 2000, but was withdrawn after failing to show clinical benefit while also having excess
mortality in 2010 (phase III NCT00085709) (74). After a re-evaluation of the dosing schedule,
toxicity was found to be reduced with more frequent doses at lower concentrations while
retaining efficacy in subsets of patients. In the phase III study NCT00927498, 271 patients aged
50 to 70 years old were randomized into two arms of 7+3 with or without mylotarg at 3mg/m 2
over 2 h on days 1, 4, and 7 of induction and day 1 of 1st and 2nd consolidations. Mylotarg
improved EFS (event free survival, 17.3 v 9.5 months) but not overall survival (27.5 v 21.8
months, not significant). Other trials have shown efficacy as single agent over BSC (best
supportive care). Overall, mylotarg is another case of an incremental success in AML targeted
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therapies as well as a reminder that optimization of dosing schedules and patient subsets to treat
can improve patient outcomes.
Vyxeos is a liposomal formulation with cytarabine and daunorubicin at a 5:1 molar ratio
to optimize synergy of the 7+3 standard of care. It was FDA approved for therapy related AML
(t-AML) and AML with myelodysplasia related changes (AML-MRC). The phase III
NCT01696084 trial, randomized 309 newly diagnosed t-AML and AML-MRC patients aged 6075 to Vyxeos or 7+3. Vyxeos was administered by IV over 90 minutes on days 1, 3, and 5 at 44
mg/m2 daunorubicin and 100 mg/m2 cytarabine and days 1 and 3 for the second induction, and at
29 and 65 mg/m2 on days 1 and 3 of consolidation. Vyxeos improved survival against 7+3 (9.56
v 5.95 months) and reduced 30 and 60 day mortality (75).
2018 continued with 4 more AML drug approvals starting with the approval of oral IDH1
inhibitor ivosidenib (Tibsovo) for patients with IDH1 mutated R/R AML. Ivosidenib
preferentially inhibits R132 mutated IDH1 over wild type IDH1 and does not inhibit IDH2 at
physically relevant concentrations. The RealTime IDH1 Assay companion test determines IDH1
R132 mutational status, which is a gain of function mutation present in about ~7% of patients
(30, 76). The approval came after the results of a phase I single arm 3+3 dose escalation trial to
determine the phase II recommended dose. 258 IDH1 mutated patients including 179 with R/R
AML received 500 mg of ivosidenib daily. 33% had a CR/CRh with a median DOR of 8.2
months. The drug was well tolerated with 38% of patients experiencing a dose interruption and
13% discontinuing treatment due to adverse events (AEs). As mutant IDH1 prevents blood cell
differentiation, differentiation syndrome must be monitored (experienced in 20% of patients). In
2019, ivosidenib was approved for de novo AML for patients with an IDH1 mutation and are
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either over 75 or chemotherapy ineligible. As with many of the other new AML therapies, OS is
poor and long term OS benefits are yet to be determined.
Glasdegib (trade name Daurismo, also known as PF-04449913), which inhibits
Smoothened in the sonic hedgehog signaling (SHH) pathway, was approved in combination with
low dose cytarabine (LDAC) for patients older than 75 or chemotherapy ineligible (77). SHH
signaling and subsequent transcription is important for regulation of differentiation and
development, is often activated in AML, and is associated with poor survival and persistence of
cancer stem cells (CSCs) (78). The phase Ib/II trial NCT01546038 recruited 114 patients who
were either older than 75 years or older than 55 years with an ECOG (Eastern Cooperative
Oncology Group) performance status of at least 2. The phase I MTD (maximum tolerated dose)
of glasdegib was 400 mg but 100 mg was chosen for the Ib/II study. At 100 mg, glasdegib
inhibited 90% of smoothened. 20 mg of LDAC was administered daily on days 1-10 of the cycle
and 100 mg glasdegib was given in one of the two arms on days 1-28 of the cycle. This
continued until disease progression or unacceptable toxicity. Despite the low statistical power of
the study (single sided α=0.1) the results were striking. Glasdegib and LDAC improved OS 8.3
vs 4.3 months in comparison to LDAC. Future trials with greater statistical power will further
determine OS differences and potential benefit in MDS.
The oral Bcl-2 inhibitor venetoclax was also approved for patients older than 75 or were
chemotherapy ineligible in combination with either azacitidine or decititabine or LDAC (79).
Bcl-2 is an anti-apoptotic protein overexpressed in AML that prevents cells death, increases
chemoresistance, and is associated with poor outcomes (80, 81). Venetoclax was approved in
CLL in 2016 and is well tolerated in older patients and patients with poor performance status. In
AML, venetoclax has shown promise but response rates as a single agent are relatively low (82).
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The approval of venetoclax was the result of two trials, the phase Ib NCT02203773 and the
phase I/II NCT02287233. Enrolled patients were newly diagnosed AML patients older than 75
years and patients older than 55 who are chemotherapy ineligible. Due to the risk of tumor lysis
syndrome (TLS, where too many tumor cells dying causes cellular contents to enter the
bloodstream with potentially toxic levels of metabolites and electrolytes), a dose escalation
schedule was used for venetoclax. The azacitidine arm was given azacitidine on days 1-7 of each
28-day cycle at 75mg/m2. The decitabine arm was given decitabine on days 1-5 of each cycle at
20 mg/m2. The LDAC arm was given LDAC on days 1-10 of each cycle on days 1-10 of each
cycle. On days 1, 2, and 3; 100, 200, and 400 mg of venetoclax were given respectively. Day 4
and beyond, 400 mg of venetoclax was given in the azacitidine or decitabine arms and 600 mg of
venetoclax in the LDAC arm. 25 of 67 patients in the azacitidine arm had a CR with a median
DOR of 5.5 months. 7 of 13 patients in the decitabine arm had a CR with a median DOR of 4.7
months. 13 of 61 patients in the LDAC arm had a CR with a median DOR of 6 months. Efficacy
will be further determined in the phase II NCT02993523 and NCT03069352 trials. While the
results are an improvement for the sensitive, older population, further improvements with
venetoclax combination therapies are needed.
The latest approval for AML is the oral FLT3 inhibitor gilteritinib (XOSPATA), which
was approved for FLT3-mutanted R/R AML (83). FLT3 status was determined by the FDA
approved LeukoStrat CDx FLT3 Mutation Assay. The approval was based on the phase III trial
NCT02421939 in which 138 R/R AML patients with a FLT3-ITD or FLT3-TKD mutation
received 120 mg of gilteritinib daily. 12% of patients had a CR with an 8.6 month median DOR
(21% CR/CRh, 4.6 month DOR). Ongoing clinical trial data after approval with additional
patients showed a survival benefit versus doctor’s choice (OS 9.3 v 5.6 months) and 8% had to
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discontinue the drug due to AEs (83). Further studies with gilteritinib combinations and other
FLT3 inhibitors are ongoing (84).
Despite these advances, many patients do not have the targetable mutations (e.g. FLT3,
IDH1/2), do not respond to, or relapse on current therapies. Even for those who do respond to
therapy, response rates and survival remain frustratingly low. In addition, many elderly patients
cannot tolerate intensive chemotherapy and forego treatment all together (14). In summary, there
remains an unmet need for more effective treatments that are tolerated by more patients in AML.

1.2 Apoptosis Pathways
All multicellular organisms depend not only on the controlled proliferation of cells, but
also on the removal and turnover of old and damaged cells (2). This process is important for
many cellular processes, including but not limited to: neuronal pruning, turnover of blood cells,
and the removal of non-functional and autoimmune lymphocytes (85). Unlike necrosis, which is
unregulated and involves the spilling of cell contents and subsequent damage to surrounding
tissues, apoptosis (programmed cell death [PCD]) is a highly regulated process that ends in
neatly packaged cell components being engulfed by phagocytes. Apoptosis is initiated by two
main pathways: internal signals (intrinsic apoptosis) and external signals and receptors (extrinsic
apoptosis) (86). In cancers including AML, avoiding apoptosis allows the cells to survive, even
when overcrowded, stressed, damaged, and/or abnormal (87).
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1.2.1 Extrinsic Apoptosis
The extrinsic apoptotic process starts with signaling from the tumor necrosis factor (TNF)
family on the surface of the cell (85) (Figure 1.3). The Fas ligand (FasL) binds to Fas, TNFα
binds to TNFR (TNF receptor), and TNF-related apoptosis inducing ligand (TRAIL) binds to
death receptors 4 and 5 (DR4/5) (88). These receptors and ligands are expressed in response to
cellular and environmental signals. Once one of these receptors is bound, the intracellular death
domain (DD) undergoes a conformational change to release the inhibitory silencer of death
domain (SODD) bound to the DD. The DD of the cellular membrane receptor can then bind to
DD of the Fas-associated protein with death domain (FADD). The death effector domain (DED)
of FADD can either be inhibited by proteins such as c-FLIP (cellular FLICE [FADD-like IL-1βconverting enzyme]-inhibitory protein) or bind to the DED of pro-caspases 8 or 10. Caspases
start as inactive zymogens (pro-caspases) which are activated by cleavage of the protein (89).
TNFα can also bind to Tumor necrosis factor receptor type 1-associated DEATH domain
(TRADD, also known as CRADD), which binds to Receptor Interacting Protein (RIP), which
binds to RIP-associated protein with a death domain (RAIDD) to bind to and activate procaspase 2 through the caspase activation and recruitment domain (CARD). Activated “initiator”
caspases 2, 8, and 10 subsequently activate “executioner” caspases 3, 6, and 7 as well as
activating pro-apoptotic Bid of the intrinsic apoptotic pathway through cleavage.
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Figure 1.3. Extrinsic apoptotic pathway. FasL is Fas ligand. DR4/5 is Death Receptor 4/5.
TRAIL is tumor necrosis factor-related apoptosis inducing ligand. TNF-α is tumor necrosis
factor α. TNFR is tumor necrosis factor receptor. DD is death domain. FADD is Fas-associated
protein with death domain. DED is death effector domain. Pro-cas is pro-caspase and cas is
caspase. Bid is BH3 Interacting Domain Death Agonist and t-Bid is truncated Bid. L and S are
the large and small subunits of caspase. c-FLIP is cellular FLICE (FADD-like IL-1β-converting
enzyme)-inhibitory protein. TRADD is Tumor necrosis factor receptor type 1-associated
DEATH domain. RIP is receptor interacting protein. RAIDD is RIP-associated protein with a
death domain. CARD is caspase activation and recruitment domain. (85, 88)
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1.2.2 Intrinsic Apoptosis
The intrinsic apoptotic pathway responds to internal cellular stresses and is a caspase and
mitochondrial dependent process (85). The balance towards survival or death can be directed by
many factors, such as the loss of growth signaling, loss of apoptotic suppression, radiation,
toxins, DNA damage, viral infections, free radicals, and hypo/hyper-thermia. The initiation of
apoptosis starts with a shift in favor of the pro-apoptotic Bcl-2 (B cell lymphoma 2) family
proteins over the anti-apoptotic Bcl-2 family members that normally sequester them (these
interactions are explained further in section 1.2.4). Eventually, pro-apoptotic family effectors
such as Bak and Bax are activated by excess pro-apoptotic activators, leading to pores on the
outer mitochondrial membrane (OMM). This leads to the release of cytochrome c (cyt c) from
the inter membrane space (IMS) of the mitochondria and the decoupling of the energy gradient
(mitochondrial outer membrane potential, MOMP) in the mitochondria (Figure 1.4). The loss of
the energy generation potential of the powerhouse of the cell, signals that the cell is starting
programmed cell death. APAF-1 (Apoptotic peptidase activating factor 1) binds to cyt c through
its WD-40 domains (repeat domain which is 40 amino acids long and ends in a tryptophanaspartic acid [W-D] dipeptide) and binds to and activates procaspase 9 through its CARD
domain, forming a heptameric complex. Initiator caspase 9 cleaves pro-caspases 3, 6, and 7 into
active caspases. SMAC (second mitochondria-derived activator of caspases, also known as
DIABLO) and Omi (Omi stress-regulated endoprotease, released by the mitochondrial pores like
cyt c) sequester XIAP (X-linked inhibitor of apoptosis) and other IAPs (inhibitors of apoptosis)
from inhibiting activator caspase activation. Subsequent steps of apoptosis include the
degradation and packing of the cellular contents, including but not limited to the cleavage of
DNA into fragments, the cleavage and degradation of DNA repair proteins such as PARP (poly

24
[ADP-ribose] polymerase), and the localization of phosphatidylserine (PS) to the outer
membrane to promote immune engulfment (90-92). The localization of PS to the inner
membrane during normal cell conditions is controlled by the ATP (adenosine triphosphate)
dependent flippase, which loses its ATP supply during apoptosis (93).

Figure 1.4. Intrinsic apoptotic pathway. cyt c is cytochrome c. SMAC is second mitochondriaderived activator of caspases. Omi is Omi stress-regulated endoprotease. CARD is caspase
activation and recruitment domain. L and S are the large and small subunits of caspase. WD-40
is the WD-40 repeat domain which is 40 amino acids long and ends in a tryptophan-aspartic acid
(W-D) dipeptide. XIAP is X-linked inhibitor of apoptosis. (85)
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1.2.3 Detecting Apoptosis
The cellular changes that occur during apoptosis can be used to observe apoptosis.
Visually, the cells will have irregular membranes that eventually fragment. These alterations in
the membrane only occur well after apoptosis has been initiated (94). DNA fragmentation
between centrosomes creates DNA “ladder” fragments of multiples of the length between
centrosomes during late apoptosis. During apoptosis and before the DNA ladder, DNA is cut in
preparation for fragmentation. These cuts can be observed by the TUNEL (terminal
deoxynucleotidyl transferase dUTP nick-end labeling) assay. These cuts can also be the result of
DNA damage, so the assay is non-specific (95). Cleavage of the DNA repair protein PARP can
also indicate that the cell is giving up on repairing DNA and undergoing apoptosis. (Both
cleavage of caspase 3 (an execution apoptotic caspase) and PARP are shown throughout the
dissertation work.) Phosphatidylserine (PS) is normally on the inside of the cell membrane but
can be expressed on the outside of the membrane during early apoptosis. This is recognized by
phagocytes which engulf the cell. Annexin V (AnnV) can bind to PS and be quantified by flow
cytometry to measure apoptotic cells (used often in the dissertation work) (96). Charged dyes
such as propidium iodide (PI) can penetrate cell membranes that are not intact (e.g. dead cells).
Mitochondrial assays can measure the maintenance of the voltage gradient necessary for energy
generation and the release of cytochrome c (97). A caveat of these assays is many of the
observations of late apoptosis coincide with dead cells in general. After cells die, they degrade
and are hard to detect in vitro (often leading to an underestimate of the number of dead cells).
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Figure 1.5. Bcl-2 Family proteins. BH is the Bcl-2 homology domain. TM is the
transmembrane domain. Bad is Bcl-2 associated agonist of cell death. PUMA is p53 upregulated
modulator of apoptosis. NOXA is Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA is
Latin for damage). Bid is BH3 interacting-domain death agonist. Bim is Bcl-2-like protein 11.
Bcl-2 is B cell lymphoma 2. Bcl-xL is B-cell lymphoma-extra large. Mcl-1 is myeloid cell
leukemia 1. Bak is Bcl-2 antagonist/killer 1. Bax is Bcl-2-associated X protein. (98)
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1.2.4 The Bcl-2 Family of proteins
The intrinsic apoptotic pathway is regulated by the Bcl-2 family of proteins which are
grouped into four categories (98). While there are over 20 Bcl-2 family proteins with a variety of
roles, we will discuss the members most relevant to AML. They are categorized by their Bcl-2
homology domains (BH) and their roles in intrinsic apoptosis (Figure 1.5).
The effectors, such as Bak (Bcl-2 Antagonist/Killer 1) and Bax (Bcl-2-associated X
protein), form oligomers, which form larger pores in the outer mitochondrial membrane which
release cytochrome c to activate apoptosis. Both Bax and Bak have BH1, BH2, and BH3
domains which form a pocket that can bind to proteins with a BH3 domain (99). BH3 only
proteins can activate effectors through a conformational change to form pores. Alternatively,
anti-apoptotic proteins can sequester effectors and inhibit apoptosis. Bak is localized to the
mitochondria and binds to Mcl-1 and Bcl-xL (B-cell lymphoma-extra large) (100). Bax is
localized in the cytosol but moves to the mitochondria upon apoptotic signaling. Bax binds to
Bcl-2, Bcl-xL, and Mcl-1 (myeloid cell leukemia 1).
The anti-apoptotic members, such as Bcl-2, Mcl-1, and Bcl-xL, can bind to and inhibit
the effectors, as well as bind to BH3 only proteins, that promote apoptosis and have BH1, BH2,
BH3, and BH4 domains (101). These proteins are often overexpressed in cancers as a way to
avoid cell death and overcome the proliferative oncogenic stresses. Bcl-2 was first implicated in
lymphomas with chromosome 14 to 18 translocations which place the highly expressed
immunoglobulin (IgG) heavy chain locus next to the Bcl-2 gene, increasing Bcl-2 protein levels
(102). Bcl-xL, like Bcl-2, is inhibited by Bad and is necessary for platelet survival (103). Mcl-1
is inhibited by NOXA and also plays a role in the DNA damage response (DDR) (104).
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The activators, such as Bim (Bcl-2-like protein 11) and Bid (BH3 interacting-domain
death agonist), possess a BH3 domain, and can activate the effectors or sequester the antiapoptotic proteins. This is also where the intrinsic and extrinsic apoptotic pathway crosstalk. Bim
binds strongly to multi-domain Bcl-2 family proteins while Bid binds less strongly to Mcl-1.
Truncated Bid (t-Bid) as a result of extrinsic or intrinsic apoptotic signaling translocates to the
mitochondria to enhance its pro-apoptotic activity (105). PUMA (p53 upregulated modulator of
apoptosis, sometime considered a direct activator) binds to Mcl-1, Bcl-2, and Bcl-xL and is
upregulated in response to stress signaling in addition to p53 (106).
The sensitizers, such as Bad (Bcl-2 associated agonist of cell death), PUMA (may be
considered an activator), and NOXA (Phorbol-12-myristate-13-acetate-induced protein 1, NOXA
is Latin for damage), also possess only a BH3 domain but are not potent enough to directly
activate the effectors at physically relevant concentrations (107). They can, however, bind to the
anti-apoptotic proteins and indirectly free up effectors and activators to induce apoptosis. Bad
binds to Bcl-2 and Bcl-xL. When phosphorylated by growth factors or other signals, Bad
becomes anti-apoptotic and acts as a link between growth and apoptotic signaling (108). NOXA
binds to Mcl-1 and can promote its degradation (109). It can compete with Mcl-1 binding to Bak
and with Bim binding to Mcl-1, preventing apoptosis inhibition (110). PUMA and NOXA may
be considered activators but are much weaker than Bim and Bid (98).
Several models have been proposed for interactions between the anti-apoptotic and proapoptotic Bcl-2 family members (Figure 1.6) (107). In the displacement model, BH3 only
proteins inhibit anti-apoptotic proteins. This allows the effectors to induce apoptosis. In the
direct activation model, sensitizers inhibit anti-apoptotic proteins which inhibit activators,
resulting in activation of effectors. The most recent embedded together model, takes into account
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reciprocal inhibition between anti-apoptotic proteins with sensitizers, activators, and effectors. It
is the culmination of affinity and concentration of these members that determine the availability
of apoptotic proteins to induce cell death.
The Bcl-2 family members also have many non-apoptotic roles, as well (111). Some of
these roles, such as Mcl-1 localizing to the nucleus to aid in DNA repair responses, relate
tangentially to the stress and damage versus survival decision that underlie the apoptotic
response. The localization of Bcl-2 family proteins can affect their function. Cytosolic proteins
such as Bax require activation to enter the OMM preventing their spurious activation as well as
providing a mechanism of control for its function. Mcl-1 can be truncated and translocated to the
mitochondrial intermembrane space (IMS) or inner mitochondrial membrane (IMM) to modulate
oxidative phosphorylation (112). Other roles for Bcl-2 family proteins include mitochondrial
fusion/fission required for mitochondrial health, the unfolded protein response (UPR), Ca2+
regulation in the endoplasmic reticulum (ER), and autophagy which involves non-apoptotic BH3
domain containing proteins such as Beclin-1 (111).
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Figure 1.6. Interaction models for Bcl-2 family proteins. (107)

1.2.5 Dysregulation of the Bcl-2 family
Too little or too much cell death can have negative effects for the organism. Excess
programmed cell death is seen in degenerative disorders, and human immunodeficiency virus
(HIV) which cleaves anti-apoptotic Bcl-2, upregulates pro-apoptotic Bax, as well as activates
extrinsic apoptosis (113, 114). A lack of apoptosis can cause excess proliferation, not only in
cancer, but also in autoimmune diseases (115). In Crohn’s disease, excess Bcl-2 leads to less T
cell death, T cell accumulation, and chronic inflammation (116). The gene Bcl-2 (B cell
lymphoma 2) is associated with diffuse large B cell lymphoma (DLBCL) and was later found to
be associated with many hematological malignancies including but not limited to CLL, multiple
myeloma (MM), ALL, and AML (80, 117-121). As cancer cells are more stressed (e.g. reliance
on growth factors due to excess proliferation, excess DNA damage and replication leading to
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increased reliance on DNA repair) they are closer to being lethally stressed. The evasion of
programmed cell death becomes more important relative to less stressed non-malignant cells.

1.2.6 Targeting the Bcl-2 family
The anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 proteins have been known to play an
important role in apoptosis dysregulation in AML (80, 117-120). Bcl-2 is a particularly attractive
therapeutic target as it is overexpressed in bulk AML and LSCs responsible for relapse and is
associated with poor prognosis (18). While inhibitors of the Bcl-2 family have been promising in
AML and other hematological malignancies, inhibition of Bcl-xL has been associated with
platelet death and thrombocytopenia (reduced platelet count) (117).
Oblimersen (G3139) was the first drug developed to target Bcl-2 to reach clinical trials in
2003 (NCT00039117) (122). This was the culmination of years of progress: the discovery of the
t(14;18) translocation in 1978, the discovery of its pro-survival function in 1988, the mechanistic
studies of intrinsic apoptosis and the development of inhibitors preclinically in the 1990’s (123).
The drug worked by delivering anti-sense RNA to bind to Bcl-2 mRNA and block translation of
the Bcl-2 protein (124). Due to a lack of efficacy, clinical trials of this drug have been stopped in
lieu of more promising agents.
ABT-737 was one of the earlier BH3 mimetics which sought to mimic the BH3 only
proteins to bind to the binding pocket formed by the BH1, BH2, and BH3 domains of the antiapoptotic proteins (125, 126). It was developed based on the crystal structure of Bcl-xL and how
it binds to its target substrates. It was able to bind to Bcl-2 and Bcl-xL with a much higher
affinity than previous BH3 mimetics. While showing good preclinical efficacy, ABT-737 was
not orally bioavailable, leading to reformulation (127).
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Navitoclax (ABT-263), a result of that reformulation, is an oral inhibitor of Bcl-2 and
Bcl-xL. However, due to its inhibition of Bcl-xL, it depleted platelets leading to dose limiting
toxicity (128). It entered the clinic in 2009 but did not gain FDA approval. It has been tested in
clinical trials in solid tumors which tend to be more Bcl-xL dependent (129, 130).
A new Bcl-2 specific inhibitor venetoclax (also known as ABT-199), improves upon its
predecessor navitoclax by not targeting Bcl-xL (131). [Note: Venetoclax was in phase I-II trials
in AML and was FDA approved for 17p deletion CLL at the start of the dissertation work. It was
approved in combination with other agents in AML on November 21, 2018. However, poor
overall survival with monotherapy remains a concern at the writing of this dissertation.] Our
group and others have reported that venetoclax has promising activity against preclinical models
of AML and other cancers (131-137). While venetoclax alone has promising clinical activity,
relapse remains a concern (average time to relapse is 2.5 months) (82, 138). Combination
therapies (e.g. with decitabine, azacitidine, or LDAC) increased remission rates and had low
early mortality but long term improvements have yet to be determined (139, 140). Survival
improvements have been modest and new therapies are needed to target AML and the LSCs
responsible for relapse.

1.2.7 Resistance to Bcl-2 inhibition through Mcl-1
Our lab and others have shown that resistant AML cell lines and patient samples
upregulate Mcl-1 in response to venetoclax treatment (86, 141). While venetoclax treatment
disrupts Bcl-2 binding to Bim, Mcl-1 compensates by binding to Bim, preventing Bim from
inducing apoptosis. We found that CRISPR (clustered regularly interspaced short palindromic
repeats) knockdown of Mcl-1 enhanced venetoclax activity in venetoclax resistant AML cells.
Mcl-1 was found to be upregulated after venetoclax treatment through increase of its protein
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stability rather than transcription. This increase in Mcl-1 protein was found to be Bim-dependent
(141).
Mcl-1 is potentially a therapeutic target for overcoming resistance to venetoclax in AML.
This can be achieved by direct targeting of Mcl-1, which is discussed in chapter 2. A-1210477
was one of the first putative Mcl-1 inhibitors available at the start of my dissertation work (142,
143). Other Mcl-1 inhibitors developed preclinically during the course of my study have
progressed into Phase I studies and are discussed in Chapter 5, future directions. Mcl-1 can be
targeted indirectly such as through protein stability which is discussed in Chapter 3. Mcl-1 is a
short-lived protein and changes in protein half-life can significantly and quickly alter its protein
levels (144, 145). Inhibition of XPO1 (exportin 1, chromosomal maintenance 1 [CRM1]) has
anti-leukemic activity and downregulates Mcl-1 which could potentially further enhance
venetoclax activity (146, 147). Mcl-1 can also be indirectly targeted transcriptionally, which is
discussed in chapter 4. Inhibition of CDK9 (cyclin dependent kinase 9) has anti-leukemic
activity and downregulates Mcl-1 transcription which could potentially enhance venetoclax
activity (148-150).

1.3 Hypothesis and Specific Aims
To test our hypothesis that targeting Mcl-1 can overcome resistance to venetoclax in
AML, my thesis work was split into three aims in chapters 2-4, respectively:
Specific Aim 1: To determine if direct targeting of Mcl-1 with A-1210477 can
synergize with venetoclax to induce apoptosis in AML cells. Our working hypothesis was that
targeting both Mcl-1 and Bcl-2 will prevent Bim sequestration, allowing Bim to activate Bak and
Bax and induce apoptosis. (Daniel A. Luedtke et al. Inhibition of Mcl-1 enhances cell death

34
induced by the Bcl-2-selective inhibitor venetoclax in acute myeloid leukemia cells. Signal
Transduction and Targeted Therapy. 2017 Apr 7; 2: 17012)
Specific Aim 2: To determine if the XPO1 selective inhibitor KPT-330 can synergize
with venetoclax to induce apoptosis in AML through downregulation of Mcl-1 protein. Our
working hypothesis was that XPO1 (exportin 1) inhibition selectively targets leukemic cells and
decreases Mcl-1 protein levels; therefore targeting XPO1 can synergize with venetoclax
treatment. (Daniel A. Luedtke et al. Inhibition of XPO1 enhances cell death induced by
venetoclax in acute myeloid leukaemia via Mcl-1. Journal of Cellular and Molecular Medicine.
2018; 22: 6099-6111)
Specific Aim 3: To determine if the CDK9 selective inhibitor voruciclib can
synergize with venetoclax to induce apoptosis in AML through decrease of Mcl-1 gene
transcription. Our working hypothesis is that CDK9 (cyclin-dependent kinase 9) inhibition
selectively targets AML cells and decreases Mcl-1 levels through transcriptional means;
therefore targeting CDK9 can synergize with venetoclax treatment. (Pending publication by
Daniel A. Luedtke et al. Inhibition of CDK9 by Voruciclib Synergistically Enhances Cell Death
Induced by the Bcl-2 Selective Inhibitor Venetoclax in Preclinical Models of Acute Myeloid
Leukemia. Signal Transduction and Targeted Therapy. Under review)
Our studies seek to understand the mechanisms of resistance to venetoclax treatment to
lead to novel approaches to overcome this resistance in AML. The proposed experiments provide
an improved understanding of the efficacy and molecular mechanisms of targeting Bcl-2 family
members for the treatment of AML.
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CHAPTER 2: DIRECT TARGETING OF MCL-1 VIA A1210477 ENHANCES VENETOLCAX ACTIVITY
This section is partly modified from the publication by Daniel A. Luedtke et al. Inhibition
of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor venetoclax in acute myeloid
leukemia cells. Signal Transduction and Targeted Therapy. 2017 Apr 7; 2: 17012

2.1 Introduction
Our previous studies showed that venetoclax treatment increased Mcl-1 levels (but not
Bcl-2 and Bcl-xL) in venetoclax-resistant AML cell lines and an AML primary patient sample ex
vivo (cells from an organism cultured in the lab) (141). Knockdown of Bim by shRNA (short
hairpin RNA) partially abolished the increase in Mcl-1 induced by venetoclax and CRISPR
knockdown of Mcl-1 enhanced venetoclax activity. This prompted our working hypothesis that
targeting both Mcl-1 and Bcl-2 will prevent Bim sequestration, allowing Bim to activate Bak and
Bax and induce apoptosis of AML cells.
Development of Mcl-1 inhibitors has been challenging due to its rigid and hydrophobic
BH3 binding pocket. Despite this, some breakthroughs were made before the start of my thesis
work in the development of Mcl-1 specific inhibitors (including A-1210477) (142). In this
chapter, we tested whether direct targeting of Mcl-1 with the specific small molecule inhibitor A1210477 could overcome venetoclax resistance in both AML cell lines and primary patient
samples.
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2.2 Materials and Methods
2.2.1 Drugs
Venetoclax and A-1210477 were purchased from Selleck Chemicals (Houston, TX).

2.2.2 Cell Culture
THP-1 and U937 cell lines were purchased from the American Type Culture Collection
(Manassas, VA). MOLM-13 was purchased from AddexBio (San Diego, CA, USA). The cell
lines were authenticated in August of 2017. The cell lines were cultured in RPMI 1640 media
with 10-20% fetal bovine serum (FBS, heat treated at 56°C for 45min and stored at 4°C, Life
Technologies, Carlsbad, CA) and 2 mM L-glutamine, plus 100 U/ml penicillin and 100 μg/ml
streptomycin, in a 37 °C humidified atmosphere containing 5% CO2/95% air, at 1-10 E5
cells/mL counted manually by hemocytometer from Recihert (Buffalo, NY) and trypan blue
(from Gibco to count dead cells, Grand Island, NY) staining. Cell lines were tested for the
presence of mycoplasma 2-3 days after thawing, monthly, and before making new freezes (151).
Cell lines were frozen in 1 mL aliquots of complete media plus 10% DMSO (dimethyl sulfoxide)
with 5 E6 cells in Nalgene cryogenic vials (Thermo Fischer, Waltham, MA) in the Mr. Frosty
Freezing container (Thermo Fischer, Waltham, MA) at -80°C to cool slowly before long term
storage in liquid nitrogen. Cell line freezes were quickly thawed in a 37°C water bath, then 9 mL
of complete media added to dilute DMSO, spun, and resuspended in fresh media.
Diagnostic AML blast samples derived from patients were purified by standard FicollHypaque density centrifugation, then cultured in RPMI 1640 with 20% fetal bovine serum, ITS
(insulin, transferrin, sodium selenite) Solution (Sigma-Aldrich, St. Louis, MO) and 20%
supernatant of the 5637 bladder cancer cell line [as a source of granulocyte-macrophage colony-
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stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin-1 beta,
macrophage colony-stimulating factor (M-CSF), and stem cell factor β (SCFβ)] (134, 152, 153).

2.2.3 Clinical Samples
Diagnostic blast samples were obtained from the First Hospital of Jilin University.
Written informed consent was provided according to the Declaration of Helsinki. This study was
approved by the Human Ethics Committee of The First Hospital of Jilin University. Clinical
samples were screened for FLT3-ITD, NPM1, C-kit, CEBPA, IDH1, IDH2 and DNMT3A gene
mutations and the following fusion genes by real-time polymerase chain reaction (RT-PCR):
PML-RARα, BCR-ABL, AML1-MDS1, MLL-AF10, MLL-AF4, MLL-ELL, SET-CAN, TLS-ERG,
NPM-RARα, E2A-PBX1, AML1-EAP, MLL-AF17, MLL-AF6, MLL-ENL, SIL-TAL1, HOX11,
PLZF-RARα, TEL-AML1, DEK-CAN, MLL-AF1p, MLL-AF9, NPM-ALK, TEL-ABL, EIP1L1PDGFRA, AML1-ETO, CBFB-MYH11, E2A-HLF, MLL-AF1q, MLL-AFX, NPM-MLF1,
dupMLL, and TEL-PDGFB. Normal peripheral blood mononuclear cells (PBMCs) were derived
from healthy donors (154, 155).

2.2.4 Western Blot Analysis
Cells were collected and spun at 1800 rpm for 5 min (Jouan CR4i centrifuge, Thermo
Electron Industries SAS, Chateau-Gontier, France) to remove most of the media and transferred
to a 1.5 mL tube to be spun on a microcentrifuge to remove the remaining media (Eppendorf
5415R, Hamburg, Germany). Cells were lysed (Heat Systems Ultrasonics W-375 Sonicator,
Qsonica, Newtown, CT) in the presence of protease (cOmplete) and phosphatase (PhosSTOP)
inhibitors (Roche Diagnostics, Indianapolis, IN) in 10 mM Tris-Cl pH 7.0 (Fisher Bioreagents,
Fair Lawn, NJ) and 0.5% sodium-dodecyl-sulfate (SDS, Sigma Life Science, St. Louis, MO).
After lysing, samples rested on ice for 20 min and were spun at 12,000 rpm for 10 min by
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microcentrifuge. Protein concentrations were measured using the DC Protein Assay kit from
BioRad (Hercules, CA) and a µQuant plate reader and the Gen5 software (BioTek Instruments,
Windowski, VT).
Western blot samples were prepared with equal protein concentrations of the whole cell
lysates and loading dye and heat treated (95°C for 5 min, PTC-200 Peltier Thermocycler, MJ
Research, Watertown, MA). A molecular weight ladder was prepared with either MagicMark XP
(Invitrogen, Carlsbad, CA) or prestained SDS-PAGE (sodium dodecyl sulfate, polyacrylamide
gel electrophoresis) standards low range (BioRad, Hercules, CA). Samples were subjected to 7.512% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for 30 min and
90V for the stacking gel phase followed by 180V for a variable time depending on the protein of
interest and gel percentage. Proteins were electrophoretically transferred onto polyvinylidene
difluoride (PVDF) membranes (Thermo Fisher Inc., Rockford, IL) for 250 mA for 90 min.
Membranes were dried, rehydrated with methanol and water, blocked with either 5% milk or
BSA, and immunoblotted with anti-Bcl-2 (ab692, Abcam, Cambridge, MA), -Bcl-xL (2764), Mcl-1 (4572), -PARP (9542), -Bim (2819), -γH2AX (2577), -Bak (3814), -Bax (2774), -cleaved
caspase-3 (9661, designated -cf caspase-3, Cell Signaling Technology, Danvers, MA), or -β-actin
(A2228, Sigma-Aldrich) antibody at 1:1000 dilution (except for β-actin at 1:10,000) overnight at
4°C or 1 h at room temperature and washed off. Secondary antibody (IRDye 680RD Goat antimouse or IRDye 800CW goat anti-rabbit, LiCor, Lincoln, NE) was applied overnight at 4°C or 1
h at room temperature and washed off. Immunoreactive proteins were visualized using the
Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE), as described by the manufacturer.
Western blots were repeated at least 3 times and one representative blot is shown. Densitometry
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measurements were made using Odyssey V3.0 (Li-Cor), normalized to β-actin on the same blot,
and calculated as the fold change compared to the corresponding no drug treatment control.

2.2.5 Annexin V/PI Staining and Flow Cytometry Analysis
AML cells were treated with venetoclax or A-1210477, alone or in combination, for 4 or
24 h and subjected to flow cytometry analysis using the Annexin V-fluorescein isothiocyanate
(FITC)/propidium iodide (PI) Apoptosis Kit (Beckman Coulter; Brea, CA). Briefly, 50 μL
resuspended cells were transferred to clean 12 × 75 culture tubes containing 50 μL Annexin-V
FITC/PI reagents in 1× binding buffer and incubated in the dark for 15 minutes. At the end of
incubation, an additional 0.4 mL of 1× binding buffer was added to each tube, vortexed, and
analyzed with the use of a Coulter XL Flow Cytometer (Coulter) equipped with an Argon laser.
Cells were gated to include the main viable cell population based on forward scatter (FS) /side
scatter (SS) characteristics (62). Cellular events with low FS/high SS character were not included
in the gate because these represent a mixture of overtly necrotic cells and apoptotic bodies that
can artificially elevate apoptosis levels. Apoptotic events from this intact cell gate were recorded
as a combination of the Annexin-V+/PI− (early apoptotic) and Annexin-V+/PI+ (late
apoptotic/dead) events. Results are expressed as percent Annexin V+. Experiments were
performed 3 independent times in triplicate. For the AML cell lines, data presented are from one
representative experiment, while patient sample experiments were performed once in triplicate
due to limited sample. Patient samples were chosen based on availability of adequate sample for
the assay. The extent and direction of anti-leukemic interaction was determined by calculating
the combination index (CI) values using CompuSyn software (Combosyn Inc., Paramus, NJ).
CI<1, CI=1, and CI>1 indicate synergistic, additive, and antagonistic effects, respectively (156,
157).
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2.2.6 Co-immunoprecipitation (Co-IP)
AML cell lines were treated for 4 h and then the cells were lysed at 4°C for 3 h or
overnight using 1% CHAPS, 5 mM MgCl2, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM
Tris, and 0.05% Tween-20 in the presence of protease inhibitors as previously described (158).
After determination of protein concentrations by the DC protein assay as described in the
Western Blotting section, 2 μg of anti-Bim (2819, Cell Signaling Technology) or anti-Mcl-1
(SC-819, Santa Cruz Biotechnology, Santa Cruz, CA) antibody, 1 mg protein lysate, and Protein
A agarose beads (Roche Diagnostics) were incubated overnight at 4°C. After washing, proteins
were eluted from the Protein A agarose beads using 50 mM glycine, pH 2.0, and then analyzed
by Western blotting.

2.2.7 shRNA Knockdown
The pMD-VSV-G and delta 8.2 plasmids were gifts from Dr. Dong at Tulane University.
Bim and non-target control (NTC) shRNA lentiviral vectors were purchased from Aldrich.
Lentivirus production and transduction were carried out according to the manufacturer’s
instructions. Briefly, TLA-HEK293T cells were transfected with pMD-VSV-G, delta 8.2, and
lentiviral shRNA constructs using Lipofectamine and Plus reagents (Life Technologies)
according to the manufacturer’s instructions. Virus containing culture medium was harvested 48
h post transfection. Cells were transduced overnight using 1 mL of virus supernatant and 4 μg of
polybrene and then cultured for an additional 48 h prior to selection with puromycin from
Invivogen (San Diego, CA). The resulting puromycin-resistant cells were used to determine the
effect of the genes of interest on AML cell sensitivity to venetoclax and/or A-1210477.

2.2.8 Alkaline Comet Assay
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U937 cells were treated for 4 h with venetoclax and/or A-1210477 and subjected to
alkaline comet assay. The harvested cells were mixed with 1.0% low melting point agarose in
PBS (phosphate buffered saline, Mg and Ca free) at 37°C. Approximately 5000 cells were
layered onto pre-coated microscope slides (pre-coated slides were coated with a thin layer of 1%
low melting point agarose and allowed to dry for 90 min), a glass coverslip was placed on top of
the cell/agarose suspension and the gels were allowed to gel for 10 min at 4°C. The slides were
then placed in lysis solution (2.5 M NaCl, 10 mM Tris, 100 mM EDTA, 10% DMSO and 1%
Triton X-100, pH 10.0) overnight at 4°C. The slides were placed in electrophoresis buffer (1 mM
EDTA, 300 mM NaOH, pH 13.0) for 40 min at 4°C to allow unwinding of the DNA.
Electrophoresis was conducted for 30 min at 30 V (1.25 V/cm). After electrophoresis, the slides
were rinsed in 400 mL distilled water, dipped in 95% ethanol and dried. DNA was stained with
1∶30,000 SYBR Gold (Life Technologies) in 10 mM Tris, pH 7.5 plus 1 mM EDTA for 40 min
at room temperature. The slides were rinsed in distilled water and imaged on an Olympus BX-40
microscope with an Olympus DP72 microscope camera and Olympus cellSens Dimension
software (Olympus America Inc., Center Valley, PA). 50 comets per gel were scored using
CometScore (TriTek Corp, Sumerduck, VA). The median percent DNA in the tail from at least
three replicate gels were averaged. The error bars indicate standard errors of the means.

2.2.9 Statistical Analysis
Differences were compared using the two-sample t-test. Statistical analyses were
performed with GraphPad Prism 5.0. Error bars represent ± s.e.m. (standard error of the mean).
The level of significance was set at p<0.05.
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2.3 Results
2.3.1 A-1210477 synergizes with venetoclax to induce apoptosis in venetoclaxresistant AML cells
To begin to test our hypothesis that Mcl-1 inhibition through A-1210477 (A) can
synergize with venetoclax (VEN), we tested various concentrations of venetoclax and A1210477, alone or in combination, in venetoclax-resistant AML cell lines (THP-1 IC50 [half
maximal inhibitory concentration] 2.4µM, and U937 IC50 13.5 µM) and a relapsed primary AML
patient sample (154). The concentrations of venetoclax used in our studies are clinically
achievable (FDA application 208573Orig1s000). The combination index (CI) was used to
determine synergy. CI=1 denotes an additive effect while CI<0.9 denotes synergy, and CI<0.3
denotes strong synergy (157). At 24 h, synergy was observed between the two drugs for THP-1
(CI<0.30) and U937 (CI<0.70) cell lines (Figure 2.1 A&B). Annexin V positive cells were
largely propidium iodide (PI) positive as well, indicating that the cells were late apoptotic or
dead (159). Annexin V/PI staining was assessed after 4 h treatment to determine if cells may
have undergone early apoptosis as venetoclax is known to show anti-leukemic activity early
(160). At 4 h, synergy was still observed for THP-1 (CI<0.002) and U937 (CI<0.74) cell lines
and a majority of the Annexin V positive cells were PI negative, indicating that the cells
underwent early apoptosis (Figure 2.1 C&D). Corroborating this, cleavage of PARP and caspase
3 was strongly enhanced in the combination treatment when compared to venetoclax or A1210477 alone in THP-1 and U937 cells (Figure 2.2). Similar results were achieved in a primary
patient sample ex vivo (Figure 2.3, patient characteristics are in Table 2.1, collect by Dr. Hai Lin,
analyzed by Xiaojia Niu). In summary, A-1210477 is able to synergize with venetoclax to induce
apoptosis in otherwise venetoclax-resistant AML cells.
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Figure 2.1. A-1210477 synergizes with venetoclax to induce apoptosis in venetoclaxresistant AML cell lines. (A-D) THP-1 and U937 cells were treated with venetoclax (VEN) and
A-1210477 (A), alone or in combination, for 4 h or 24 h and then subjected to Annexin V/PI
staining and flow cytometry analyses. ***indicates p<0.001. Combination index (CI) values
were calculated using CompuSyn software. VEN, venetoclax. A, A-1210477. These
abbreviations are used throughout this chapter.
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Figure 2.2. A-1210477 cooperates with venetoclax to induce cleavage of caspase 3 and
PARP in venetoclax-resistant AML cell lines. (A&B) THP-1 and U937 cells were treated with
venetoclax or A-1210477 alone or in combination for 4 h. Whole cell lysates were subjected to
Western blotting and probed with the indicated antibodies.

45

Figure 2.3. A-1210477 synergizes with venetoclax to induce apoptosis in a venetoclaxresistant relapsed primary AML patient sample ex vivo. (A&B) Primary AML patient sample
AML#110 was treated with venetoclax and A-1210477, alone or in combination, for 24 h and
then subjected to Annexin V/PI staining and flow cytometry analyses (panel A). Whole cell
lysates were subjected to Western blotting and probed with the indicated antibodies (panel B).
***indicates p<0.001. CI values were calculated using CompuSyn software. Patient
characteristics are shown in Table 2.1.
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2.3.2 A-1210477 treatment increases Mcl-1 protein levels but releases Bim
from Mcl-1
Having observed the synergy between venetoclax and A-1210477, the next question was
to determine how treatment affected levels of relevant Bcl-2 proteins and their interactions.
Protein levels of Bcl-2, Mcl-1, Bcl-xL, and Bim were determined by Western blotting. Individual
treatment with venetoclax or A-1210477 caused increased levels of Mcl-1 without changing the
levels of Bcl-2, Bim, and Bcl-xL in THP-1, U937, and a primary AML patient sample derived at
relapse (Figure 2.4 A-C). The occupation of the BH3 binding pocket by Bim or A-1210477 can
prevent Mcl-1 degradation and ubiquitination through competition with E3 ligases (141, 161).
Combination treatment appeared to decrease Mcl-1 levels compared to A-1210477 alone, though
levels remained similar to or higher than that in vehicle control treated cells, suggesting that
disruption of the interaction of Mcl-1 with Bcl-2 family proteins played a critical role in the
synergistic effects. To determine if interaction of Bcl-2 family members with Bim were disrupted
by drug treatments, co-IP was performed. A-1210477 disrupted the interaction between Bim and
Mcl-1 (Figure 2.4 D), which surprisingly occurred despite the presence of elevated Mcl-1. The
binding of Bim with Bcl-2 was disrupted by venetoclax and not A-1210477 (Figure 2.4 E). The
binding of Bim with Bcl-2 and Mcl-1 was disrupted by the combination treatment. Bcl-xL,
another anti-apoptotic Bcl-2 family member which binds to Bim, did not compensate for this
disruption, indicating that Bim was possibly unbound, freeing it to carry out its pro-apoptotic
role.
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Figure 2.4. A-1210477 treatment increases Mcl-1 protein levels but releases Bim from Mcl1. (A-C) THP-1, U937, and primary AML patient sample cells (AML#110) were treated with
venetoclax and A-1210477, alone or in combination, for 4 h or 24 h. Whole cell lysates were
subjected to Western blotting and probed with the indicated antibodies. Relative densitometry
measurements of Mcl-1 expression were measured using Odyssey Software V3.0 and normalized
to actin and the no drug control. (D&E) U937 cells were treated with venetoclax and A-1210477,
alone or in combination, for 4 h. Mcl-1 (panel D) or Bim (panel E) was immunoprecipitated from
whole cell (WC) lysates and then subjected to Western blotting and probed with the indicated
antibodies. Relative densitometry measurements of Mcl-1, Bim, and Bcl-2 were measured using
Odyssey Software V3.0 and normalized to actin and the no drug control (panels A-C) or to no
drug control (panels D&E). *indicates the light chain of the anti-Mcl-1 or -Bim antibody.
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2.3.3 The effect of Bim, Bax, and Bak knockdown on apoptosis induced by
venetoclax and A-1210477 in AML cells
To confirm the contribution of Bim to apoptosis induced by venetoclax and A-1210477
combined treatment, shRNA knockdown was performed. Knockdown of Bim in U937 and THP1 (Figure 2.5 A&C) significantly reduced apoptosis in response to A-1210477 and combined
treatment in both cell lines (Figure 2.5 B&D). Bim knockdown also significantly reduced
apoptosis induced by venetoclax in THP-1 cells (Figure 2.5 D). Bak and Bax individual
knockdowns were performed in U937 cells due to the critical roles they play in the execution of
the intrinsic apoptotic pathway (Figure 2.6 A). As expected, knockdown of Bax or Bak
(especially Bak, which binds preferentially to Mcl-1) also reduced apoptosis significantly in the
A-1210477 and combined treatments (Figure 2.6 B) (107). These results demonstrate that the
canonical pathway of intrinsic apoptosis including Bim, Bak, and Bax plays an important role in
induction of apoptosis in response to A-1210477 treatment alone or in combination with
venetoclax.
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Figure 2.5. The effect of Bim knockdown on apoptosis induced by venetoclax and A1210477 in AML cell lines. (A&C) U937 (panel A) or THP-1 (panel C) cells were infected with
non-template control (NTC) or Bim-shRNA lentivirus. Whole cell lysates were subjected to
Western blotting and probed with the indicated antibodies to confirm the knockdown. Relative
densitometry measurements of Bim protein were measured using Odyssey Software V3.0 and
normalized to actin and NTC. (B&D) U937 (panel B) or THP-1 (panel D) shRNA knockdown
(KD) cells were treated with venetoclax and A-1210477, alone or in combination, for 4 h and
then subjected to Annexin V/PI staining and flow cytometry analyses. *indicates p<0.05,
**indicates p< 0.01, and ***indicates p<0.001.

50

Figure 2.6. The effect of Bax and Bak knockdown on apoptosis induced by venetoclax and
A-1210477 in AML cell lines. (A) U937 cells were infected with non-template control (NTCshRNA)-, Bax-, or Bak-shRNA lentivirus. Whole cell lysates were subjected to Western blotting
and probed with the indicated antibodies to confirm the knockdowns. (B) The U937 Bax and Bak
knockdown (KD) cells were treated with venetoclax and A-1210477, alone or in combination,
for 4 h and then subjected to Annexin V/PI staining and flow cytometry analyses. ***indicates
p<0.001.
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2.3.4 A-1210477 induces DNA damage in AML cells
Mcl-1 has a known role in both apoptosis and the DNA damage response (104). Our lab
previously demonstrated that venetoclax treatment enhances DNA damage induced by DNA
damaging agents (141, 160), thus the question remained whether the synergistic action of A1210477 combined with venetoclax was due to apoptosis and/or DNA damage. γ-H2AX
(phosphorylated H2A histone family member X), a surrogate marker for DNA damage was
measured by Western blot (162). The level of γ-H2AX increased following venetoclax or A1210477 treatment, and increased after combined treatment in THP-1, U937, and a patient
sample (Figure 2.7 A). However γ-H2AX levels can indicate late apoptosis, as well. To further
elucidate the extent of DNA damage, the comet assay was performed. DNA damage, as
measured by alkaline comet assay (Figure 2.7 B&C), increased dramatically with A-1210477
treatment but not venetoclax treatment. Interestingly, combination treatment did not further
increase DNA damage compared to A-1210477 treatment. While A-1210477 may induce some
apoptosis by DNA damage, its synergistic interaction with venetoclax is not due to DNA damage
and is likely due to the apoptotic function of Mcl-1.
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Figure 2.7. A-1210477 induces DNA damage in AML cells. (A) THP-1, U937, and a primary
AML patient sample (AML#110) were treated with venetoclax and A-1210477, alone or in
combination, for 4 h or 24 h. Whole cell lysates were subjected to Western blotting and probed
with the indicated antibody. Relative densitometry measurements of γH2AX protein were
measured using Odyssey Software V3.0 and normalized to actin and the no drug control. (B)
U937 cells were treated with venetoclax and A-1210477, alone or in combination, for 4 h and
then subjected to alkaline comet analyses. Representative images are shown. (C) Comet assay
results are graphed as median percent DNA in the tail from 4 replicate gels ± s.e.m. *indicates
p<0.05 and **indicates p<0.01.
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2.3.5 A-1210477 synergizes with venetoclax in venetoclax-sensitive AML cells
To further increase the clinical relevance of the study, A-1210477 and venetoclax
combination treatment was performed in venetoclax-sensitive MOLM-13 cells, newly diagnosed
AML patient samples, and normal peripheral blood mononuclear cells (PBMCs). Treatment of
MOLM-13 with venetoclax and A-1210477 synergistically induced apoptosis (Figure 2.8 A,
CI<0.16), accompanied by caspase 3 and PARP cleavage (Figure 2.8 B). Similar to resistant cell
lines, Bcl-2 and Bim levels were unchanged and Mcl-1 was induced by A-1210477 treatment
alone (Figure 2.8 C). However, Mcl-1 was not detected after combined treatment, potentially due
to Mcl-1 degradation resulting from caspase activation. Treatment of three newly diagnosed
AML patient samples with A-1210477 and venetoclax synergistically induced apoptosis, as well
(CI<0.40, CI<0.49, CI<0.05, respectively, Figure 2.9 A&B, work by Dr. Hai Lin and Xiaoji
Niu). In several relatively venetoclax-sensitive and -resistant AML cell lines and patient samples,
venetoclax and A-1210477 combination treatment synergistically induced apoptosis, suggesting
that this combination works regardless of venetoclax sensitivity.
Lastly, to test the effects of combined treatment on normal cells in addition to AML cells,
PBMCs derived from 5 healthy donors were subjected to single drug treatment of either
venetoclax or A-1210477 to determine IC50 values. Venetoclax IC50 values ranged from 5.5 M
to 48.3 M, while A-1210477 IC50 values ranged from 3.3 M to 7.1 M (Figure 2.10 A). IC50
values were also determined for A-1210477 in the presence of set concentrations of venetoclax
(Figure 2.10 B). It was found that A-1210477 and venetoclax act synergistically to reduce viable
normal PBMCs albeit at higher concentrations than in AML (Figure 2.11), indicating that a
potential therapeutic window could be found.
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Figure 2.8. A-1210477 synergizes with venetoclax in venetoclax-sensitive MOLM-13 AML
cell line. (A) MOLM-13 cells were treated with venetoclax and A-1210477, alone or in
combination, for 4 h and then subjected to Annexin V/PI staining and flow cytometry analyses.
***indicates p<0.001. CI values were calculated using CompuSyn software. (B&C) MOLM-13
cells were treated with venetoclax and A-1210477, alone or in combination, for 4 h. Whole cell
lysates were subjected to Western blotting and probed with the indicated antibodies. Relative
densitometry measurements of Mcl-1 expression were measured using Odyssey Software V3.0
and normalized to actin and the no drug control.
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Figure 2.9. A-1210477 synergizes with venetoclax in venetoclax-sensitive primary AML
patient samples ex vivo. Newly diagnosed primary AML patient sample cells (AML#111-113)
were treated with venetoclax and A-1210477, alone or in combination, for 24 h and then
subjected to Annexin V/PI staining and flow cytometry analyses. ***indicates p<0.001. CI
values were calculated using CompuSyn software. Patient characteristics are shown in Table 2.1.
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Figure 2.10. Effect of A-1210477 or venetoclax on normal PBMCs ex vivo. MTT assays were
performed on normal PBMCs at the indicated concentrations of venetoclax (panel A) or A1210477 (panel B) for 72 h. Patient sample data are means of duplicates due to limited sample.
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Figure 2.11. A-1210477 synergizes with venetoclax in normal PBMCs ex vivo. MTT assays
were performed on normal PBMCs at the indicated concentrations of A-1210477 and venetoclax,
alone or in combination, for 72 h. Patient sample data are means of duplicates due to limited
sample. Standard isobologram analyses of anti-leukemic interactions were performed to
determine the extent and direction of the anti-leukemic interactions. The IC50 values of each drug
are plotted on the axes; the solid line represents the additive effect, while the points represent the
concentrations of each drug resulting in 50% inhibition of proliferation. Points falling below the
line indicate synergism whereas those above the line indicate antagonism.
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Patient

Gender Age
(years)

Disease
Status

FAB
subtype

Cytogenetics Blast
purity
(%)

AML#110 Female
AML#111 Male

66
58

Relapsed
Newly
diagnosed

M4
M2

45, XX, -7
46, XY

48.0
63.5

AML#112 Male

46

Newly
diagnosed

M1

46, XY

92.0

AML#113 Female

10

Newly
M5
46, XX
97.0
diagnosed
Table 2.1. Patient characteristics for primary AML patient samples.

Gene
mutation

CEBP
double
mutation,
DNMT3A
mutation,
GATA2
mutation
CEBP
double
mutation
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2.4 Discussion
Relapse in cancer is due to remaining cells that are not targeted by therapy and are able to
reconstitute the tumor. In AML, it is believed that the largely quiescent leukemic stem cells are
able to avoid chemotherapy and cause relapse (18). Bcl-2 was found to be overexpressed in bulk
AML and LSCs, prompting the clinical development of the Bcl-2 inhibitor venetoclax (163,
164). However, relapse remains a concern (median time to relapse was 2.5 months) (82, 138).
We previously reported that the Chk1 inhibitor LY2603618 induces DNA damage,
decreases Mcl-1 levels alone and in combination with venetoclax (160). We have also shown
that DNA damage induced by chemotherapy is enhanced by venetoclax (141, 165). Mcl-1 plays
a role in the DNA damage response (166). While it is plausible that DNA damage induced by A1210477 could be enhanced by venetoclax, enhanced DNA damage was not observed in the
combination, ruling out the role of DNA damage in the synergy of the combination.
While targeting of both Bcl-2 and Mcl-1 synergized to induce apoptosis in AML cells,
the treatment also synergistically decreased viable PBMCs, albeit at higher concentrations.
While direct inhibition of Mcl-1 may be toxic, indirect inhibition of Mcl-1 may prove to be more
effective. Multiple anti-leukemic therapies can also downregulate Mcl-1 and can potentially
synergize with venetoclax. As Mcl-1 has a short protein half-life compare to other Bcl-2 family
members, targeting Mcl-1 protein stability or transcript levels can be used to effectively enhance
the anti-leukemic activity of venetoclax.
In summary, we found that inhibition of Mcl-1 by A-1210477 enhanced venetoclaxinduced apoptosis in venetoclax-sensitive and -resistant AML cell lines in vitro and primary
patient samples ex vivo. The enhancement in activity was at least partially dependent on the
intrinsic apoptotic pathway. Venetoclax prevents the binding of Bim to Bcl-2. In venetoclax-
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sensitive cells it is plausible that without increases in Mcl-1 there is not enough Mcl-1 to fully
sequester Bim. This results in free Bim which can activate Bak/Bax and lead to apoptosis. In
venetoclax-resistant cells, Mcl-1 binds to Bim freed by venetoclax. A-1201477 disrupts the
interaction between Bim and Mcl-1, freeing Bim to activate Bak/Bax and induce apoptosis. A
caveat is that A-1210477 is merely a research tool to validate the target of Mcl-1. With the
validation of the efficacy of targeting both Bcl-2 and Mcl-1, the question remains as to how to
target Mcl-1 in a clinically relevant and leukemic specific manner.

61

Figure 2.12. Proposed mechanism for the synergy between A-1210477 and venetoclax in
AML cells. Venetoclax treatment (black arrows) releases Bim from Bcl-2. In venetoclaxsensitive cells, there is an inadequate amount of Mcl-1 to sequester all of the released Bim,
resulting in free Bim, which can then activate Bak/Bax, leading to apoptosis. In venetoclaxresistant cells, the Bim released from Bcl-2 is sequestered by Mcl-1 (blue arrows), leading to
stabilization of Mcl-1, and ultimately resulting in survival. In the combined drug treatment,
addition of A-1210477 abolishes sequestration of Bim by Mcl-1 (red arrows), allowing Bim to
activate Bax/Bak, resulting in enhanced apoptosis.
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CHAPTER 3: INHIBITION OF XPO1
DOWNREGULATES MCL-1 AND ENHANCES
VENETOLCAX ACTIVITTY
This section is partly modified from the publication by Daniel A. Luedtke et al. Inhibition
of XPO1 enhances cell death induced by venetoclax in acute myeloid leukaemia via Mcl-1.
Journal of Cellular Molecular Medicine 2018; 22: 6099-6111.

3.1 Introduction
After having shown the efficacy of direct targeting Bcl-2 and Mcl-1 in Chapter 2, we
sought to target Mcl-1 using clinically tested compounds through indirect mechanisms. Exportin
1 (XPO1), also known as Chromosome Region Maintenance 1 (CRM1), is a protein which
regulates the nuclear export of client proteins and has been found to play a critical role in many
cancers including prostate cancer, ovarian cancer, osteosarcoma, glioma, cervical cancer, CLL,
Non-Hodgkin’s lymphoma (NHL), MM, and AML (146, 167-170).
As a nuclear exporter, XPO1 plays a critical role in the localization of many proteins as
well as some mRNA transcripts, and has been shown to be required for survival of solid tumors
and hematological malignancies (146, 147, 171-175). XPO1 is also the sole exporter for many
tumor suppressor proteins including, but not limited to, p53, p73, FOXO, IκB, Rb, p21, and
NPM (176). XPO1 inhibition has also been shown to synergize with DNA damaging agents,
which potentially could synergize with venetoclax, which is known to weaken the DNA damage
response (177, 178). KPT-330 (also known as selinexor) is a XPO1-selective inhibitor that is
currently being tested in phase I and phase II clinical trials for hematological malignancies and
solid tumors (NCT02091245, NCT02530476, NCT02249091, NCT02419495, NCT02343042,
and NCT02178436). After the submission of this paper, selinexor was approved for penta-
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refractory MM (179). Preclinical results show that KPT-330 induces responses at well-tolerated
doses (180) and decreases Mcl-1 protein levels (171). Higher XPO1 levels are associated with
poor prognosis and targeting XPO1 by KPT-330 has shown promise in clinical trials in targeting
AML (146, 147). Our working hypothesis was that because XPO1 inhibition decreases Mcl-1
levels, targeting XPO1 can synergize with venetoclax treatment, which is known to synergize
with Mcl-1 inhibition. In addition, KPT-330 has been shown to not only eliminate the rapidly
proliferating bulk AML cells but also LSCs (180). Therefore, it was conceivable that KPT-330
may synergize with venetoclax in eradicating both bulk AML cells and LSCs.

3.2 Materials and Methods
3.2.1 Drugs
Venetoclax, KPT-330 (selinexor), KPT-8602 (eltanexor) and MG-132 were purchased
from Selleck Chemicals (Houston, TX). Cycloheximide was purchased from Sigma-Aldrich (St
Louis, MO, USA).

3.2.2 Cell Culture
MV4-11 and THP-1 cell lines were purchased from the American Type Culture
Collection (Manassas, VA, USA). CTS was a gift from Dr. A Fuse from the National Institute of
Infectious Diseases (Tokyo, Japan). OCI-AML3 was purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). MOLM-13 was purchased
from AddexBio (San Diego, CA, USA). Cell lines were authenticated in August 2017 at the
Genomics Core at Karmanos Cancer Institute using the PowerPlex® 16 System from Promega
(Madison, WI, USA). The cell lines were cultured as described in section 2.2.2.
Diagnostic AML blast samples derived from patients either at initial diagnosis or at
relapse were purified by standard Ficoll-Hypaque density centrifugation, then cultured in RPMI
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1640 with 20% fetal bovine serum, ITS Solution (Sigma-Aldrich, St. Louis, MO) and 20%
supernatant of the 5637 bladder cancer cell line (as a source of GM-CSF, G-CSF, interleukin-1
beta, M-CSF, and SCFβ) (134, 152, 153).

3.2.3 Clinical Samples
Diagnostic AML blast samples were obtained from the First Hospital of Jilin University.
Written informed consent was provided according to the Declaration of Helsinki. This study was
approved by the Human Ethics Committee of The First Hospital of Jilin University. Clinical
samples were screened for gene mutations by automated DNA sequencing and fusion genes by
real-time RT-PCR, as described in section 2.2.3 (154, 155).

3.2.4 Western Blot Analysis
See section 2.2.4 for complete details. Anti-Bcl-2 (ab692, Abcam, Cambridge, MA), Bcl-xL (2764), -Mcl-1 (4572), -PARP (9542), -Bim (2819), -Bak (3814), -Bax (2774), -cleaved
caspase-3 (9661, designated –cf-Cas3, Cell Signaling Technology, Danvers, MA), or -β-actin
(A2228, Sigma-Aldrich) antibody at 1:1000 dilution (except for anti-β-actin antibody at
1:10,000) antibodies were used.

3.2.5 Annexin V/PI Staining and Flow Cytometry Analysis
AML cells were treated with venetoclax, KPT-330, or KPT-8602, alone or in
combination, and subjected to flow cytometry analysis using the Annexin V-FITC/PI Apoptosis
Kit (Beckman Coulter; Brea, CA). See section 2.2.5 for details.

3.2.6 shRNA Knockdown
Please see section 2.2.7.

3.2.7 Co-Immunoprecipitation (Co-IP)
See section 2.2.6.
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3.2.8 CRISPR knockdown
The lentiCRISPRv2 plasmid was a gift from Feng Zhang at the Broad Institute of MIT
and Harvard [Addgene plasmid #52961 (29)]. Guide RNAs were designed using the CRISPR
design tool (http://CRISPR.mit.edu). The NTC and Mcl-1 vectors were generated using Feng
Zhang's protocol, which is available on Addgene's website (www.addgene.org). Lentivirus
production and transduction were carried out as described above in "shRNA Knockdown,"
except that psPAX2 (gift from Didier Trono at the Swiss Institute of Technology, Addgene
plasmid # 12260) was used instead of delta 8.2.

3.2.9 Colony Forming Assay
Primary AML patient samples were treated with either venetoclax or KPT‐330, alone or
in combination, for 24 h. The cells were washed three times with PBS and then the cells were
plated in methylcellulose in media and allowed to incubate at 37 °C humidified atmosphere
containing 5% CO2/95% air for 14-16 days. Colonies (colony forming units [CFUs], more than
50 cells/CFU) were manually counted under a microscope. Technical triplicates were performed.

3.2.10 Real-time (RT-PCR)
Total RNA was extracted using TRIzol (Life Technologies) and cDNAs (complementary
DNA) were prepared from 2 µg total RNA using random hexamer primers and a RT-PCR Kit
(Life Technologies), and then purified using the QIAquick PCR (polymerase chain reaction)
Purification Kit (Qiagen) as described previously (181). Mcl-1 (Hx01050896_m1) and GAPDH
(Hs99999905_m1) transcripts were quantitated using TaqMan probes (Life Technologies) and a
LightCycler 480 real-time PCR machine (Roche Diagnostics), based on the manufacturer's
instructions. Real-time PCR results were expressed as means from three independent
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experiments and were normalized to GAPDH transcripts. Fold changes were calculated using the
comparative Ct method (182).

3.2.11 Statistical Analysis
All data was checked graphically for conformity with the assumptions of the normal
theory linear model and transformations applied if necessary. Statistical significance was
evaluated with Welch’s t-test to compare two groups and Analysis of Variance (ANOVA) (183)
for comparing groups of 3 or more samples with Tukey or Bonferroni correction to control the
type 1 error rate. After analysis, models were evaluated for fit and the possible existence of
influential points. Statistical analyses were performed with GraphPad Prism 5.0. Error bars
represent ± s.e.m. The level of significance was set at p<0.05.

3.3 Results
3.3.1 Inhibition of XPO1 synergizes with venetoclax in AML cell lines
To begin to test our hypothesis that KPT-330 can synergize with venetoclax to induce
apoptosis, we tested various clinically achievable concentrations of venetoclax and KPT-330,
alone and in combination, in five AML cell lines (FDA application 212306Orig1s000). The CI
was used to determine drug synergy (157). At 24 h, synergy was observed between the two drugs
in THP-1 (CI<0.02), OCI-AML3 (CI<0.31), MV4-11 (CI<0.12), MOLM-13 (CI<0.55), and CTS
(CI<0.27) cell lines (Figure 3.1). Corroborating this, cleavage of PARP and caspase 3 was
strongly enhanced in the combination treatment when compared to venetoclax or KPT-330 alone
in THP-1, OCI-AML3, and MV4-11 cells (Figure 3.2). To further confirm our results, we used a
second generation XPO1 inhibitor and KPT-330 analog, KPT-8602. At 24 h, synergy was
observed between KPT-8602 and venetoclax in THP-1 (CI<0.30), OCI-AML3 (CI<0.16), and
MV4-11 (CI<0.04) cell lines (Figure 3.3). Consistent with KPT-330, cleavage of PARP and
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caspase 3 was strongly enhanced in the combination treatment when compared to venetoclax or
KPT-8602 alone in the cell lines (Figure 3.4). In summary, XPO1 inhibition synergizes with
venetoclax to induce apoptosis in AML cell lines.
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Figure 3.1. Inhibition of XPO1 by KPT-330 synergizes with venetoclax in AML cell lines.
THP-1 (A), MV4-11 (B), OCI-AML3 (C), MOLM-13 (D), and CTS (E) cells were treated with
venetoclax or KPT-330, alone or in combination, for 24 h and then subjected to Annexin VFITC/PI staining and flow cytometry analyses. *** indicates p<0.001. Combination index (CI)
values were calculated using CompuSyn software.
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Figure 3.2. Inhibition of XPO1 by KPT-330 cooperates with venetoclax in inducing caspase
3 and PARP cleavage in AML cell lines. THP-1 (A), OCI-AML3 (B), and MV4-11 (C) cells
were treated with venetoclax or KPT-330, alone or in combination, for 24 h. Whole cell lysates
were subjected to Western blotting and probed with the indicated antibodies.
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Figure 3.3. Inhibition of XPO1 by KPT-8602 synergizes with venetoclax in AML cell lines.
THP-1 (A), OCI-AML3 (B), and MV4-11 (C) cells were treated with venetoclax or KPT-8602,
alone or in combination, for 24 h and then subjected to Annexin V-FITC/PI staining and flow
cytometry analyses. *** indicates p<0.001. Combination index (CI) values were calculated using
CompuSyn software.

71

Figure 3.4. Inhibition of XPO1 by KPT-8602 cooperates with venetoclax in inducing
caspase 3 and PARP cleavage in AML cell lines. THP-1 (A), OCI-AML3 (B), and MV4-11
(C) cells were treated with venetoclax or KPT-8602, alone or in combination, for 24 h. Whole
cell lysates were subjected to Western blotting and probed with the indicated antibodies.
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3.3.2 KPT-330 downregulates Mcl-1 and disrupts its interaction with Bim
Having observed the synergy between venetoclax and KPT-330 or KPT-8602, we sought
to determine how the combination treatment affected levels of Bcl-2 family proteins. In
agreement with our previous studies, Mcl-1 levels increased in response to venetoclax treatment
in the venetoclax-resistant cell lines (THP-1 and OCI-AML3), but not the venetoclax-sensitive
cell line (MV4-11; Figure 3.5) (141, 143). In concordance with our hypothesis, KPT-330
treatment decreased Mcl-1 levels and was able to prevent upregulation of Mcl-1 induced by
venetoclax. In contrast, the levels of Bcl-2, Bak, Bax, and Bcl-xL remained largely unchanged.
Curiously, KPT-330 treatment alone or in combination with venetoclax decreased levels of Bim.
This would be expected to reduce apoptosis. However, based on the previous figure, the overall
effect is the induction of apoptosis. Thus, the effects of Mcl-1 downregulation likely
predominate. KPT-8602 had similar effects as KPT-330 on Mcl-1 levels alone and in
combination with venetoclax (Figure 3.6). At the time when this project was ongoing, KPT-330
was more advanced in clinical development than KPT-8602, therefore KPT-330 was used in the
rest of experiments in this chapter and is labeled as KPT.
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Figure 3.5. Modulation of Bcl-2 family proteins after Bcl-2 inhibition by venetoclax and
XPO1 inhibition by KPT-330. THP-1 (A), OCI-AML3 (B), and MV4-11 (C) cells were treated
with venetoclax or KPT-330, alone or in combination, for 24 h. Whole cell lysates were
subjected to Western blotting and probed with the indicated antibodies. Relative densitometry
measurements were measured using Odyssey Software V3.0 and normalized to actin and no drug
control.
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Figure 3.6. Modulation of Bcl-2 family proteins after Bcl-2 inhibition by venetoclax and
XPO1 inhibition by KPT-8602. THP-1 (A), OCI-AML3 (B), and MV4-11 (C) cells were
treated with venetoclax or KPT-8602 alone or in combination for 24 h. Whole cell lysates were
subjected to Western blotting and probed with the indicated antibodies. Relative densitometry
measurements were measured using Odyssey Software V3.0 and normalized to actin and no drug
control.
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To further understand the role of Bcl-2 family proteins in the apoptosis induced drug
treatment, a timecourse experiment was performed. Apoptosis, determined by flow cytometry,
started between 4-8 h for the combination treatment in THP-1 cells (Figure 3.7 A). Curiously, at
8 h, Mcl-1 levels were largely unchanged in response to KPT-330 treatment (Figure 3.7 B).
However, co-IP of Bim shows that at 8 h KPT-330 prevents increased Mcl-1 binding to Bim in
response to venetoclax treatment (Figure 3.8 A). This was further confirmed by reciprocal Mcl-1
co-IP (Figure 3.8 B). Bim levels remained unchanged by drug treatment (Figure 3.8 A). Further,
Mcl-1 levels were increased in both venetoclax treatment alone and in combination with KPT330. This shows that before total protein levels of Mcl-1 and Bim change, their interaction is
disrupted by KPT-330 when in combination with venetoclax. Knockdown of Bim, partially
rescued the THP-1 cells from apoptosis, confirming the role of Bim in response to venetoclax
and KPT-330 treatment (Figure 3.8 C&D).
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Figure 3.7. Time dependent effect of XPO1 and Bcl-2 inhibition on Bcl-2 family proteins
and cell apoptosis. (A) THP-1 cells were treated with venetoclax and KPT-330, alone or in
combination, for the indicated time and then subjected to Annexin V/PI staining and flow
cytometry analyses. * indicates p<0.05 and *** indicates p<0.001. (B) THP-1 cells were treated
with venetoclax or KPT-330, alone or in combination, for the indicated time. Whole cell lysates
were subjected to Western blotting and probed with the indicated antibodies. Relative
densitometry measurements were measured using Odyssey Software V3.0 and normalized to
actin and no drug control.
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Figure 3.8. Interaction between Bim, Bcl-2, and Mcl-1 in response to XPO1 and Bcl-2
inhibition at 8 h. (A&B) THP-1 cells were treated with venetoclax and KPT-330, alone or in
combination, for 8 h. Bim or Mcl-1 were immunoprecipitated from whole cell lysates and then
subjected to Western blotting and probed with the indicated antibodies (n=2). Relative
densitometry measurements of Mcl-1, Bim, and Bcl-2 were measured using Odyssey Software
V3.0 and normalized to no drug control. *indicates the light chain of IgG. WC lysate indicates
whole cell lysate. (C&D) shRNA knockdown of Bim was generated with the indicated nontemplate control (NTC). Whole cell lysates were subjected to Western blotting and probed with
the indicated antibodies to confirm the knockdown. For panel C, relative densitometry
measurements measured using Odyssey Software V3.0 and normalized to actin and NTC. *
indicates p<0.05 (n=3) compared to the control for densitometry measurements. For panel D,
shRNA knockdown cells were treated with venetoclax and KPT-330, alone or in combination,
for 24 h and then subjected to Annexin V/PI staining and flow cytometry analyses. ** indicates
p<0.01 and *** indicates p<0.001.
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Consistent with the 8 h treatment and previous studies from our lab, 24 h venetoclax
treatment substantially increased binding of Mcl-1 to Bim, which was prevented by the addition
of KPT-330 (Figure 3.9 A). These results were confirmed by reciprocal immunoprecipitation
with a Bim antibody (Figure 3.9 B). Interestingly, KPT-330 treatment resulted in increased
binding of Bim to Bcl-2, which was abolished by combination with venetoclax. To further
determine the role of Mcl-1 in venetoclax- and KPT-330-induced apoptosis, a CRISPR
knockdown of Mcl-1 and pLOC overexpression (OE) of Mcl-1 were developed in the THP-1 cell
line (Figure 3.10 A&C). Consistent with our previous studies and our hypothesis, Mcl-1
knockdown significantly enhanced venetoclax activity (Figure 3.10 B). Interestingly, it also
enhanced combination treatment of venetoclax and KPT-330. Mcl-1 overexpression partially
rescued the cells from drug treatment (Figure 3.10 D). The incomplete rescue may be due to the
Mcl-1 overexpression not being high enough and/or Mcl-1-independent mechanisms through
which KPT-330 acts. Mcl-1 transcript levels were not decreased by venetoclax or KPT-330
treatment in both THP-1 and OCI-AML3 cells (Figure. 3.11 A&B). To test Mcl-1 protein halflife, cells were treated with or without KPT-330 for 12 h, then washed and cultured in the
presence of the protein translation inhibitor cycloheximide (CHX) for up to 120 minutes. KPT330 treatment resulted in significantly shorter Mcl-1 half-life in both THP-1 and OCI-AML3
cells (Figure 3.11 C&D). Treatment with the proteasome inhibitor MG-132 prevented
downregulation of Mcl-1 by KPT-330 (Figure. 3.11 E&F). In summary, Mcl-1 is modulated by
KPT-330 treatment alone and in combination with venetoclax, and this modulation of Mcl-1
plays an important role in apoptosis in response to drug treatment.
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Figure 3.9. Interaction between Bim and Bcl-2 or Mcl-1 in response to XPO1 and Bcl-2
inhibition at 24 h. THP-1 cells were treated with venetoclax and KPT-330, alone or in
combination, for 24 h. Bim (A) or Mcl-1 (B) were immunoprecipitated from whole cell lysates
and then subjected to Western blotting and probed with the indicated antibodies (n=2). Relative
densitometry measurements of Mcl-1, Bim, and Bcl-2 were measured using Odyssey Software
V3.0 and normalized to the no drug control. *indicates the light chain of IgG. WC lysate, whole
cell lysate.
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Figure 3.10. Role of Mcl-1 in apoptosis induced by KPT-330 and venetoclax, alone or
combined. (A&C) CRISPR knockdown of Mcl-1 and PLOC overexpression of Mcl-1 were
generated with indicated controls (NTC and RFP [red fluorescent protein]). Whole cell lysates
were subjected to Western blotting and probed with the indicated antibodies to confirm the
knockdown or overexpression. Relative densitometry measurements of Mcl-1 expression were
measured using Odyssey Software V3.0 and normalized to actin and the control. (B&D) The
cells were treated with venetoclax or KPT-330, alone or in combination, for 24 h and then
subjected to Annexin V/PI staining and flow cytometry analyses. *** indicates p<0.001.
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Figure 3.11. Regulation of Mcl-1 protein levels by XPO1 inhibition. (A&B) THP-1 and OCIAML3 cells were treated with venetoclax and KPT-330, alone or in combination for 24 h. RNA
was extracted with TRIzol and subjected to RT‐PCR analysis and normalized to the GAPDH
rRNA control and the no drug control. (C&D) THP-1 and OCI-AML3 cells were treated with or
without KPT-330 for 12 h followed by CHX treatment (10 μg/mL) and collected at the indicated
times. Whole cell lysates were subjected to Western blotting and probed with Mcl-1 and actin
antibodies. (E&F) THP-1 and OCI-AML3 cells were treated with MG-132 or KPT-330, alone or
in combination, for 24 h. Whole cell lysates were subjected to Western blotting and probed with
the indicated antibodies. Relative densitometry measurements of Mcl-1 and were measured using
Odyssey Software V3.0 and normalized to actin and the no drug control.
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3.3.3 KPT-330 synergizes with venetoclax in primary AML patient samples
To determine if KPT-330 can synergize with venetoclax to induce apoptosis in primary
AML patient samples ex vivo, we tested various concentrations of venetoclax and KPT-330,
alone and in combination, in ten primary AML patient samples (Patient characteristics are shown
in Table 3.1, samples were collected by Dr. Hai Lin and analyzed by Yongwei Su). At 24 h,
synergy was observed between the two drugs for all samples (Figure 3.12 and 3.13). Cleavage of
PARP and caspase 3 was strongly enhanced in the combination treatment when compared to
venetoclax or KPT-330 alone (Figure 3.14). Similar to AML cell lines, KPT-330 alone and in
combination with venetoclax decreased Mcl-1 levels. Next, we performed colony forming assays
on primary AML patient samples post drug treatment and found that combination treatment
significantly enhanced inhibition of colony formation (AML-CFUs, colony forming units) when
compared to single drug treatment (Figure 3.15), indicating that the combined drug treatment
decreased leukemia progenitor cells. In summary, venetoclax and KPT-330 can cooperate to
induce apoptosis in AML cell lines in vitro and primary patient sample bulk AML cells ex vivo.
The combination also cooperates to inhibit AML progenitor cells ex vivo.
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Figure 3.12. KPT-330 synergizes with venetoclax to induce apoptosis in relapsed primary
AML patient samples ex vivo. Primary AML patient samples derived from patients at relapse
were treated with venetoclax and/or KPT-330 for 24 h and then subjected to Annexin V-FITC/PI
staining and flow cytometry analyses. *** indicates p<0.001. Combination index (CI) values
were calculated using CompuSyn software. Patient characteristics are shown in Table 3.1.
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Figure 3.13. KPT-330 synergizes with venetoclax to induce apoptosis in newly diagnosed
primary AML patient samples ex vivo. Primary AML patient samples derived from patients at
initial diagnosis were treated with venetoclax and/or KPT-330 for 24 h and then subjected to
Annexin V-FITC/PI staining and flow cytometry analyses. *** indicates p<0.001. Combination
index (CI) values were calculated using CompuSyn software. Patient characteristics are shown in
Table 3.1.
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Figure 3.14. KPT-330 cooperates with venetoclax to induce apoptosis in primary AML
patient samples ex vivo. Primary AML patient samples were treated with venetoclax or KPT330, alone or in combination, for 24 h. Whole cell lysates were subjected to Western blotting and
probed with the indicated antibodies. Relative densitometry measurements were measured using
Odyssey Software V3.0 and normalized to actin and no drug control. Patient characteristics are
shown in Table 3.1.
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Figure 3.15: KPT-330 synergizes with venetoclax to reduce colony formation in primary
AML patient samples ex vivo. Primary AML patient samples were treated with venetoclax and
KPT-330, alone or in combination, for 24 h and then plated in methylcellulose (n=3). Colonies
(CFU) were counted manually. # indicates p<0.05 versus control. ## indicates p<0.01 versus
control. ### indicates p<0.001 versus control. ** indicates p<0.01 versus single drug treatment.
*** indicates p<0.001versus single drug treatment. Patient characteristics are shown in Table
3.1.
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Patients

Gender Age
Disease
(year) status

FAB
subtype

Cytogenetics

Blast
purity
(%)

Gene
mutation
CEBPα double
mutation
CEBPα double
mutation

AML#114 Female

60

Relapsed

M2

46, XX

69.0

AML#115 Male

40

Newly
diagnosed

M2

46, XY

88.5

AML#116 Female

51

Relapsed

M5

46, XX

94.0

AML#121 Male

49

Relapsed

M2

46, XY

79.5

AML#122 Male

45

M2

24

M5

47, XY, -8,
+11, +14
46, XY

78.0

AML#123 Male

92.0

CNSL

AML#124 Male

19

Newly
diagnosed
Newly
diagnosed
Newly
diagnosed

Flt-3 ITD,
NPM1,
DNMT3A
Flt-3 ITD,
NPM1
Dup MLL

M4

46, XY

62.5

AML#126 Female

60

Relapsed

M2

46, XX

49.0

AML#127 Male

77

M4

NA

NA

AML#128 Male

66

M5

46, XY

41.0

ND

AML#130 Male

66

Newly
diagnosed
Newly
diagnosed
Newly
diagnosed

CEBPA
double
mutation, cKit, NRAS,
GATA2, Flt-3
S451F
CEBPA
double
mutation
NA

M2

46，XY

NA

AML#131 Female

40

CEBPA
double
mutation
NPM-1, IDH1
NA

Newly
M4
46, XX
53.5
diagnosed
AML#132 Female 48
Newly
M2
NA
61.0
diagnosed
Table 3.1. Patient characteristics of primary AML patient samples. NA, not available; ND,
not detected.
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3.4 Discussion
For the Chapter 3 aim, we sought to expand upon the work of Chapter 2 by targeting
Mcl-1 through indirect means in a clinically relevant manner. Inhibition of XPO1 by KPT-330
and KPT-8602 was previously found to downregulate Mcl-1, target leukemic stem cells, and
spare normal hematopoietic stem cells (180, 184). It was theorized that the Mcl-1
downregulation could synergize with Bcl-2 inhibition in AML.
XPO1 is the best studied nuclear exporter. Its aberrant overexpression is associated with
poor prognosis and drug resistance in many cancers including but not limited to prostate,
ovarian, osteosarcoma, glioma, cervical, CLL, NHL, MM, and AML. It is believed that export of
growth promoters to the cytoplasm and export of tumor suppressor proteins that function by
altering transcription in the nucleus can cause excess proliferation. Inhibition of XPO1 through
early inhibitors like leptomycin B proved to have anti-tumor efficacy but were toxic due to nonreversible inhibition of XPO1 (185).
The next generation selective inhibitors of nuclear export (SINEs) like KPT-330
(selinexor) and KPT-8602 (eltanexor, developed after our studies were underway) were
developed to address this potential therapeutic target. Due to their slowly reversible binding to
their target, the compounds remained effective while also being less toxic. It was previously
reported that KPT-330 in CLL decreased Mcl-1 by decreasing mRNA levels. In contrast, we
found that in AML KPT-330 did not decrease Mcl-1 through mRNA but rather through
decreased Mcl-1 protein stability. Surprisingly, Mcl-1 downregulation happened after the
timepoint where elevated apoptosis was found in the combination. However, at 8 h we still found
disruption of Bim binding to Mcl-1 post drug treatment, even without decreased Mcl-1 levels.
KPT-330 treatment also resulted in increased binding of Bim to Bcl-2 indicating that venetoclax
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and KPT-330 reciprocally overcome resistance to single drug treatment. It is unknown how
KPT-330 disrupts Bim binding to Mcl-1 but it may be due to post-translational modifications in
Bim or Mcl-1, which warrants future study.
Both venetoclax and KPT-330 modulate Mcl-1 through protein stability. Stability of Mcl1 is affected by phosphorylation sites (altered by CDK1, CDK2, GSK3β, p38, JNK, ERK, etc.)
and binding to Bim, both of which alter the binding of E3 ligases (such as Mule, β-TrCP, FBW7,
Trim17, SCFβ) to Mcl-1 (144). Bim binds to the BH3 binding domain used by E3 ligases.
Deubiquitinases (such as USP9X and USP28) can also counteract E3 ligases by removing
ubiquitin. Also, while the bulk of the combination’s activity was recapitulated through Mcl-1
knockdown, Mcl-1 overexpression did not completely rescue the cells. As is the case with small
molecule inhibitors and the targeting of broad nuclear export activity, other factors may play a
role in drug activity and resistance that could guide clinical use.
In addition to questions about the mechanism of action of the drugs alone and in
combination, questions about tolerability and selectivity remain. The concentrations used in this
study were clinically achievable, increasing the likelihood of future success. Bcl-2 and XPO1 are
also both upregulated in leukemic stem cells and their inhibition has been found to selectively
target these cells. The combination enhanced single drug treatment in reducing both bulk AML
patient blasts and reducing the leukemic progenitor cells ex vivo. Further tolerability and efficacy
could be tested in in vivo studies and selectivity could be tested against normal peripheral blood
cells and hematopoietic stem cells.
In summary, KPT-330 synergizes with venetoclax to induce apoptosis in AML cell lines
and primary patient samples ex vivo at clinically relevant concentrations. The combination
enhances single drug activity to target leukemic progenitor cells of primary patient samples ex
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vivo. Further studies to determine the mechanism in vitro and efficacy and tolerability in vivo are
warranted.
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CHAPTER 4: INHIBITION OF CDK9
DOWNREGULATES MCL-1 THROUGH DECREASED
TRANSCRIPTION AND ENHANCES VENETOCLAX
ACTIVITY
This section is partly modified from the pending publication by Daniel A. Luedtke et al.
Inhibition of CDK9 by Voruciclib Synergistically Enhances Cell Death Induced by the Bcl-2
Selective Inhibitor Venetoclax in Preclinical Models of Acute Myeloid Leukemia. Signal
Transduction and Targeted Therapy. Under review.

4.1 Introduction
In chapters 2 and 3 we demonstrated that targeting Mcl-1 directly or targeting Mcl-1
indirectly through downregulation of its protein stability can enhance venetoclax activity. As
Mcl-1 has a short protein half-life, inhibition of Mcl-1 transcript levels could plausibly be used to
enhance venetoclax activity. CDK9, which regulates the positive transcription elongation factor
complex b (p-TEFb) through phosphorylation of RNA polymerase II (RNAP II), regulates many
pro-survival genes including but not limited to Mcl-1, Cyclin D1, and c-Myc (186, 187).
Inhibition of CDK9 with flavopiridol (alvocidib, a pan-CDK inhibitor in phase II trials in AML
and tolerable in elderly patients) can downregulate Mcl-1 and enhance venetoclax treatment in
AML (148-150). However, as a pan-CDK inhibitor, off target toxicity remains a concern. A
second generation CDK9 selective inhibitor, voruciclib, was developed. Voruciclib has greater
specificity for CDK9 than flavopiridol (188). Voruciclib was also found to downregulate Mcl-1
and synergize with venetoclax in DLBCL in vitro and in vivo (in life [e.g. mouse model]) (188).
However, the molecular mechanisms underlying the synergistic interaction between venetoclax
and CDK9 inhibition are not fully understood.
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In this chapter we found that voruciclib synergizes with venetoclax to induce apoptosis in
both AML cell lines and primary patient samples. Further, voruciclib transiently downregulates
Mcl-1, which plays a role in the synergy between voruciclib and venetoclax. Interestingly,
downregulation of c-Myc by voruciclib also contributes to its synergy with venetoclax.
Simultaneous inhibition of c-Myc and knockdown of Mcl-1 show further enhancement of
apoptosis induced by venetoclax than inhibition of c-Myc or knockdown of Mcl-1 alone.
Furthermore, an every other day schedule seems optimal for the combination of venetoclax and
voruciclib in an AML cell lined-derived xenograft model.

4.2 Materials and Methods
4.2.1 Drugs
Venetoclax (ABT-199), flavopiridol (alvocidib), Z-VAD-FMK (a pan-caspase inhibitor),
and 10058-F4 (a c-Myc inhibitor) were purchased from Selleck Chemicals (Houston, TX).
Voruciclib was provided by MEI Pharma Inc. (San Diego, CA, USA).

4.2.2 Cell Culture
See section 2.2.2 for details.

4.2.2 Clinical Samples
See section 2.2.3 for details.

4.2.3 Western Blot Analysis
See section 2.2.4 for details.
anti-Mcl-1 (4572), -PARP (9542), -Bim (2819), -Bak (3814), -Bax (2774), -c-Myc
(5605S), -cleaved caspase-3 (9661, designated –cf-Cas3, Cell Signaling Technology, Danvers,
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MA), or -β-actin (A2228, Sigma-Aldrich) antibody at 1:1000 dilution (except for the anti-β-actin
antibody at 1:10,000) were used.

4.2.4 Annexin V-FITC/PI Staining and Flow Cytometry Analysis
AML cells were treated with venetoclax, flavopiridol, voruciclib, Z-VAD-FMK, or
10058-F4, alone or in combination, and subjected to flow cytometry analysis using the Annexin
V-FITC/PI Apoptosis Kit (Beckman Coulter; Brea, CA). See section 2.2.5 for details.

4.2.5 Co-Immunoprecipitation (Co-IP)
See section 2.2.6 for details.

4.2.6 shRNA Knockdown and pLOC overexpression
shRNA knockdown and pLOC overexpression were performed as described in section
2.2.7 with the following changes. Precision LentiORF Mcl‐1 and RFP lentivirus vector were
purchased from Dharmacon (Lafayette, CO, USA). Selection for overexpression was done using
blasticidin.

4.2.7 CRISPR knockdown
See section 3.2.8 for details.

4.2.8 Real-time (RT-PCR)
Total RNA was extracted and cDNAs were prepared, and then purified) as described in
section

3.2.10.

c-Myc

transcripts

were

quantified

using

forward

(5’-

GTGGTCTTCCCCTACCCTCT-3’) and reverse (5’-CGAGGAGAGCAGAGAATCCG-3’)
primers. Real-time PCR results are expressed as means from three independent experiments and
normalized to GAPDH transcripts measured by forward (5’-AGCCACATCGCTCAGACA-3’)
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and reverse (5’-GCCCAATACGACCAAATCC-3’) primers and SYBR green. Fold changes
were calculated using the comparative Ct method. (182)

4.2.9 Cell line derived xenograft
NSG-SGM3 mice (NSGS, JAX#103062; non-obese diabetic scid gamma (NOD.CgPrkdcscid Il2rgtm1Wjl Tg(CMV-IL3, CSF2, KITLG)1Eav/MloySzJ; Jackson Laboratory, Bar
Harbor ME, USA) were injected by IV (intravenous) through tail vein with 1 E6 MV4-11
cells/mouse (day 0) and treated Q2D (every other day) from day 3 through day 31 (first day of
leukemia symptoms detected in control mice) for a total of fifteen injections. Treatment cohorts
consisted of 25 mg/kg/inj venetoclax p.o. (per os, oral) and/or 200 mg/kg/inj voruciclib p.o.. A
group of vehicle treated mice was included as a control and there were 5 mice included in all
arms. Average mouse body weights for the study was 22.4 +/- 1 g at treatment start with body
weight and condition monitored 1-2 times daily for the duration of the study.
In a separate trial, NSGS mice were injected by IV through tail vein with 1 E6 MV4-11
cells/mouse (day 0) and treated from day 3 through day 27 (first day of leukemia symptoms
detected in control mice). Treatment cohorts consisted of 25 mg/kg/inj venetoclax p.o. (daily for
5 days, one day off, followed by 19 days, for a total of 24 injections) and/or 16 mg/kg/inj PalmoAra-C i.p. Q3D (every three days, for a total of 9 injections [inj] intraperitoneal [i.p.]). A group
of vehicle treated mice was included as a control and there were 5 mice included in all arms.
Average mouse body weights for the study was 24.2 +/- 1 g at treatment start with body weight
and condition monitored 1-2 times daily for the duration of the study.
Experimental endpoint and efficacy response for both trials was determined for each
group based on the median day for development of leukemic symptoms (hind leg weakness,
>15% weight loss, metastatic spread to internal organs). % increase in lifespan (%ILS) was
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calculated: % ILS = [T-C/C] x 100 where “T” = treated and “C” = control median day of death.
All mice were provided food and water ad libitum, given supportive fluids and supplements as
needed, and housed within an AAALAC (Association for Assessment and Accreditation of
Laboratory Animal Care International) accredited animal facility with 24/7 veterinary care and
were sacrificed by CO2 asphyxiation when they showed signs of terminal illness, including hind
limb paralysis, inability to eat or drink, and/or moribund. All animal experiments were approved
by the Institutional Animal Care and Use Committee of Wayne State University.

4.2.10 Statistical Analysis
Differences were compared utilizing two-sample t-test. Error bars represent ± s.e.m.;
significance level was set at p<0.05 and adjusted for multiple comparisons with the Bonferroni
correction. One-way ANOVA (analysis of variance) was used to compare differences between 3
or more groups with Dunnett correction when compared to control or Bonferroni correction
when compared to single drug treatments. Overall survival probability was estimated using the
Kaplan-Meier method and statistical analysis was performed using the Mantel-Cox test. All the
statistical analyses were performed utilizing GraphPad Prism 5.0.

4.3 Results
4.3.1 Voruciclib induces apoptosis in AML cell lines and primary patient
samples
To begin to test the anti-leukemic activity of voruciclib (VOR), we tested various
clinically achievable concentrations (189, 190) in 5 AML cell lines and 3 primary AML patient
samples (Figure 4.1 A). Single drug treatment induced high levels of Annexin V+ cells
(determined by Annexin V/PI staining and flow cytometry analyses) in all 5 AML cell lines and
2 out of the 3 primary patient samples (patient characteristics are in Table 4.1), with moderate
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activity in the third primary patient sample. Voruciclib treatment caused substantially increased
cleavage of caspase 3 and PARP at higher concentrations (Figure 4.1 B), confirming the flow
cytometry data and demonstrating that voruciclib induces apoptosis of AML cells.

4.3.2 Voruciclib synergizes with venetoclax in AML cell lines
Having shown the anti-leukemic activity of single drug treatment, we sought to determine
the effect of voruciclib on apoptosis induced by venetoclax. AML cell lines were treated with
various concentrations of venetoclax and voruciclib, alone or in combination, for 24 h. Apoptosis
induced by the drug treatments was determined by Annexin V/PI staining and flow cytometry
analyses. The CI was used to determine the extent and direction of anti-leukemic interactions
(34). MV4-11, U937, THP-1, and MOLM-13 cell lines treated with venetoclax plus voruciclib at
clinically achievable concentrations resulted in significantly increased Annexin V+ cells
compared to single drug treatment (CI<0.73, Figure 4.2), demonstrating the efficacy and synergy
of the combination treatment.
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Figure 4.1. CDK9 inhibition induces apoptosis in AML cell lines and primary patient
samples. (A) THP-1, U937, MOLM-13, MV4-11, and OCI-AML3 AML cell lines and primary
patient samples were treated with voruciclib for 24 h and then subjected to Annexin V-FITC/PI
staining and flow cytometry analyses. (B) Whole cell lysates were subjected to Western blotting
and probed with the indicated antibodies. VOR, voruciclib; cf, cleaved form; and Cas3, caspase
3. These abbreviations are used throughout this chapter. Patient characteristics are in Table 4.1.
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Figure 4.2. Voruciclib synergizes with venetoclax to induce apoptosis in AML cells. MV4-11
(A), U937 (B), THP-1 (C), and MOLM-13 (D) cell lines were treated with venetoclax or
voruciclib, alone or in combination, for 24 h and then subjected to Annexin V-FITC/PI staining
and flow cytometry analyses. CI values were calculated using CompuSyn software. *** indicates
p<0.001.
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4.3.3 Transient Mcl-1 downregulation by CDK9 inhibition enhances
venetoclax-induced apoptosis
Next, we began to determine the mechanism by which the combination induced
apoptosis, particularly modulation of Mcl-1. In concordance with previous studies by our lab and
others (3, 17), venetoclax-resistant cells (THP-1) but not venetoclax-sensitive cells (MV4-11)
showed an increase of Mcl-1 protein in response to venetoclax treatment (Figure 4.3).
Interestingly, CDK9 inhibition by voruciclib resulted in a transient downregulation of Mcl-1
protein, which rebounded after 12 h of drug treatment in both MV4-11 and THP-1 cell lines.
However, this transient downregulation was sufficient to keep Mcl-1 levels below the control
when the cells were treated with the combination of voruciclib and venetoclax (Figure 4.3 A&B,
upper panels). Similar results were also obtained with flavopiridol (FLV) in both cell lines
(Figure 4.3 A&B, lower panels). Mcl-1 transcript levels also decreased after treatment with
voruciclib alone, which was further decreased by venetoclax treatment, potentially due to
apoptosis induced by the drug combination. Curiously, in THP-1, but not MV4-11, Mcl-1
transcripts rebounded in response to voruciclib treatment indicating that besides the
transcriptional mechanism, the rebound of Mcl-1 protein may also involve modulation of protein
stability (Figure 4.4).
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Figure 4.3. CDK9 inhibition induces transient Mcl-1 protein downregulation. MV4-11 (A)
and THP-1 (B) cells were treated with venetoclax, voruciclib (upper panels) or flavopidiol (lower
panels), alone or in combination, for the indicated times. Whole cell lysates were subjected to
Western blotting and probed with the indicated antibodies. Relative densitometry measurements
were determined using Odyssey Software V3.0 and normalized to actin and the no drug control.
FLV: flavopiridol.
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Figure 4.4. CDK9 inhibition induces transient Mcl-1 transcript downregulation. MV4-11
(A) and THP-1 (B) cells were treated with venetoclax or voruciclib, alone or combined, for 6 or
24 h. RNA was extracted with TRIzol and subjected to RT‐PCR analysis and normalized to the
18S rRNA control and the no drug control. *** indicates p<0.001 versus control and ###
indicates p<0.001 versus single drug treatment.
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Given the important role Mcl-1 plays in the intrinsic resistance to venetoclax in AML
cells (17); we sought to determine if the transient downregulation of Mcl-1 would enhance
venetoclax-induced apoptosis. At 6 h, voruciclib significantly and greatly enhanced apoptosis
induced by venetoclax (Figure 4.5 A&B). This was accompanied by greatly enhanced cleavage
of caspase 3 and PARP in the combination treatment (Figure 4.5 C&D). To further increase the
clinical relevance of our study, we tested three primary AML patient samples ex vivo and striking
synergy was observed between venetoclax and voruciclib (Figure 4.6, CI<0.07). Taken together,
our results show that voruciclib transiently downregulates Mcl-1, which may contribute to the
synergy between voruciclib and venetoclax.
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Figure 4.5. Voruciclib enhances apoptosis induced by venetoclax in AML cell lines. (A&B)
MV4-11 and THP-1 cells were treated with venetoclax or voruciclib, alone or in combination,
for 6 h and then subjected to Annexin V-FITC/PI staining and flow cytometry analyses. ***
indicates p<0.001. (C&D) MV4-11 and THP-1 cells were treated with venetoclax or voruciclib,
alone or in combination, for 6 h. Whole cell lysates were subjected to Western blotting and
probed with the indicated antibodies.
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Figure 4.6. Voruciclib enhances apoptosis induced by venetoclax in primary AML patient
blasts ex vivo. Primary AML patient samples were treated with venetoclax or voruciclib, alone
or in combination, for 6 h and then subjected to Annexin V-FITC/PI staining and flow cytometry
analyses. *** indicates p<0.001. CI values were calculated using CompuSyn software. Patient
characteristics are in Table 4.1.

105

4.3.4 The intrinsic apoptotic pathway is partially responsible for the
cooperation of voruciclib and venetoclax to induce apoptosis
To further determine the role of Mcl-1 and the intrinsic apoptotic pathway in apoptosis
induced by the combination, we performed co-immunoprecipitation of Mcl-1 in AML cell lines.
Voruciclib alone or in combination with venetoclax was able to greatly decrease the binding of
Mcl-1 to Bim in MV4-11 and THP-1 cells at 6 h (Figure 4.7). Mcl-1 knockdown (~80%
compared to NTC) was able to moderately but significantly enhance single drug treatment, but
did not significantly affect the highly efficacious combination treatment (Figure 4.8 A&B).
Inversely, Mcl-1 overexpression was able to partially rescue MV4-11 cells from single and
combination treatment (Figure 4.8 C&D). To further test the role of the intrinsic apoptotic
pathway, Bax or Bak individual knockdown and Bax/Bak double knockdown were performed.
Knockdown of Bak, which has a higher affinity to Mcl-1 than Bax, was able to completely
rescue the cells from voruciclib treatment (Figure 4.9). Knockdown of Bax or Bak led to a
modest rescue of the cells from venetoclax treatment and its combination with voruciclib.
Bax/Bak double knockdown was able to completely rescue the cells from voruciclib and
venetoclax treatment, while partially rescuing the cells from the combination treatment (Figure
4.9). These results demonstrate that apoptosis induced by the single and combination treatment
was at least partially dependent upon the intrinsic apoptotic pathway.

106

Figure 4.7. CDK9 inhibition overcomes enhanced Bim binding to Mcl-1 induced by
venetoclax. MV4-11 (A) and THP-1 (B) cells were treated with venetoclax or voruciclib, alone
or in combination, for 6 h. Cell lysates were immunoprecipitated from whole cell lysates and
then subjected to Western blotting and probed with the indicated antibodies. Relative
densitometry measurements of Mcl-1 and Bim were measured using Odyssey Software V3.0 and
normalized to the no drug control. * indicates the light chain of IgG. # indicates a non-specific
band.
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Figure 4.8. Apoptosis induced by voruciclib and venetoclax, alone or combined, is at least
partially through downregulation of Mcl-1. (A&B) CRISPR knockdown (KD) of Mcl-1 and
pLOC overexpression (OE) of Mcl-1 were generated with the indicated control (non-target
control [NTC] and red fluorescent protein [RFP]) in the indicated cell lines. Whole cell lysates
were subjected to Western blotting and probed with the indicated antibodies to confirm the KD
or OE. Relative densitometry measurements were determined using Odyssey Software V3.0 and
normalized to the control and actin. (C&D) Cells were treated with venetoclax or voruciclib,
alone or in combination, for 6 h and then subjected to Annexin V-FITC/PI staining and flow
cytometry analyses. **indicates p<0.01 and *** indicates p<0.001.
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Figure 4.9. Apoptosis induced by voruciclib and venetoclax, alone or combined, is at least
partially through the intrinsic apoptotic pathway. (A) shRNA KD of Bax, Bak, and Bax/Bak
were generated with the indicated control (non-target control [NTC]) in THP-1 cells cell lines.
Whole cell lysates were subjected to Western blotting and probed with the indicated antibodies
to confirm the KD. Relative densitometry measurements were determined using Odyssey
Software V3.0 and compared normalized to the control and actin. (B) Cells were treated with
venetoclax or voruciclib, alone or in combination, for 6 h and then subjected to annexin VFITC/PI staining and flow cytometry analyses. *** indicates p<0.001, and ns indicates not
significant.
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4.3.5 Downregulation of c-Myc and Mcl-1 enhances venetoclax-induced
apoptosis
CDK9 promotes transcription of genes encoding pro-survival factors, including c-Myc,
which plays a critical role in leukemogenesis and drug resistance in AML (149, 191, 192). Thus,
it is conceivable that CDK9 inhibition downregulates c-Myc leading to enhancement of
apoptosis induced by venetoclax. CDK9 inhibition for 6 h with voruciclib alone or in
combination with venetoclax caused major downregulation of c-Myc protein in both MV4-11
and THP-1 cells (Figure 4.10 A&B). Unlike the effect on Mcl-1, c-Myc protein levels did not
rebound after extended treatment with voruciclib (Figure 4.10 C&D). Transcripts of c-Myc were
also greatly decreased by voruciclib alone and in combination with venetoclax (Figure 4.10 E-F),
suggesting a transcriptional mechanism by which voruciclib downregulates c-Myc expression.
The pan-caspase inhibitor Z-VAD-FMK (Z-VAD) showed that induction of apoptosis by
voruciclib, alone or in combination with venetoclax was entirely caspase dependent (Figure
4.11). To determine the functional contribution of c-Myc downregulation to the anti-leukemic
activity of venetoclax, we used the c-Myc inhibitor 10058-F4. Treatment of MV4-11 and THP-1
cells with 10058-F4 modestly decreased c-Myc protein, but significantly and greatly enhanced
venetoclax induced apoptosis (Figure 4.12), which was further enhanced when Mcl-1 was
knocked down in the cells (Figure 4.13). These results demonstrate that both c-Myc and Mcl-1
are important factors involved in the synergy between venetoclax and voruciclib. Further, to
achieve maximal efficacy for the combination of voruciclib and venetoclax, both c-Myc and
Mcl-1 need to be downregulated.
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Figure 4.10. Voruciclib downregulates c-Myc in AML cells. (A-D) MV4-11 and THP-1 cells
were treated with venetoclax or voruciclib, alone or in combination, for 6 h or 24 h. Whole cell
lysates were subjected to Western blotting and probed with the indicated antibodies. Relative
densitometry measurements were determined using Odyssey Software V3.0 and normalized to
the no drug control and actin. (E&F) RNA was extracted with TRIzol and subjected to RT‐PCR
analysis and normalized to the 18S rRNA control and the no drug control.
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Figure 4.11. CDK9 inhibition enhances venetoclax activity in a caspase dependent manner.
(A-B) MV4-11 and THP-1 cells were treated with venetoclax, voruciclib, or Z-VAD-FMK,
alone or in combination, for 6 h and were subjected to annexin V/PI staining and flow cytometry
analyses. ** indicates p<0.01, *** indicates p<0.001 by t-test compared to treatment without ZVAD-FMK with Bonferroni correction. Z-VAD is Z-VAD-FMK. This abbreviation is used
throughout the manuscript.
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Figure 4.12. Inhibition of c-Myc enhances venetoclax-induced apoptosis. (A&B) MV4-11
and THP-1 cells were treated with venetoclax or 10058-F4, alone or in combination, for 6 h and
then subjected to Annexin V/PI staining and flow cytometry analyses. *** indicates p<0.001.
(C&D) Whole cell lysates were subjected to Western blotting and probed with the indicated
antibodies. Relative densitometry measurements were determined using Odyssey Software V3.0
and normalized to the no drug control and β-actin.
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Figure 4.13. Downregulation of both c-Myc and Mcl-1 maximally enhances venetoclaxinduced apoptosis. (A) CRISPR knockdown (KD) of Mcl-1 was generated with the indicated
control (NTC) in THP-1 cells. Whole cell lysates were subjected to Western blotting and probed
with the indicated antibodies to confirm the KD. Relative densitometry measurements were
determined using Odyssey Software V3.0 and normalized to NTC and actin. (B) Cells were
treated with venetoclax and 10058-F4, alone or in combination, for 6 h and then subjected to
annexin V-FITC/PI staining and flow cytometry analyses. *** indicates p<0.001.
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4.3.6 Intermittent CDK9 inhibition enhances venetoclax activity in vitro and in
vivo
To determine if retreatment of AML cells with voruciclib will cause re-downregulation of
Mcl-1, we designed experiments as shown in Figure 4.14 A. We started by treating MV4-11 cells
for 24 h with 2000 nM voruciclib. Then, the cells were washed and resuspended in fresh media.
The pretreated cells were treated with venetoclax and voruciclib alone or in combination for 6 h
immediately after cell wash or after a 24 h waiting period to allow the cells to “recover”.
Retreatment of the pretreated cells with voruciclib immediately after cell wash neither caused
obvious change of Mcl-1 protein levels nor significantly enhanced apoptosis induced by
venetoclax (0 h wait, 6 h retreatment; Figure 4.14 B&C). Conversely, pretreated cells that had a
24 h treatment “break” were more responsive to CDK9 inhibition alone, and in combination with
venetoclax based on the changes of Mcl-1 protein levels and extent of apoptosis induction. These
results were found to be similar with flavopiridol (data not shown).

115

Figure 4.14. Intermittent CDK9 inhibition enhances venetoclax activity in vitro. (A)
Schematic for the rechallenge treatments. (B) MV4-11 cells were treated with voruciclib alone
for 24 h. The cells were spun and washed with PBS. Cells were cultured in drug-free medium for
0 or 24 h, then treated as indicated for 6 h. Whole cell lysates from retreated cells were subjected
to Western blotting and probed with the indicated antibodies. Relative densitometry
measurements were determined using Odyssey Software V3.0 and normalized to the no drug
control and actin. (C) Cells treated as shown in panel A were subjected to annexin V/PI staining
and flow cytometry analyses. *** indicates p<0.001.
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Based on our in vitro voruciclib data, a Q2D dosing schedule was chosen for our in vivo
studies (performed by Dr. Lisa Polin and AMTEC). 1 E6 MV4-11 cells were injected into NSGS
mice via tail vein on day 0. Treatment started on day 3 and continued every other day until day
31 (the first day leukemia symptoms in control mice were detected). A total of fifteen injections
were given for each single agent as monotherapy or in combination with mice receiving either:
25 mg/kg/inj venetoclax p.o., 200 mg/kg/inj voruciclib p.o., or in combination (Figure 4.15 A).
Body weight loss nadir for all treatment groups was ≤ 2.7%, indicative of well-tolerated
treatment regimens (Figure 4.15 B). Venetoclax or voruciclib treatment did not extend median
survival (43 days) compared to vehicle control treatment (43 days), however the combination of
voruciclib and venetoclax modestly improved median survival (52 days, p<0.05, Mantel-Cox;
20.9% ILS; Figure 4.15 C).
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Figure 4.15. Intermittent CDK9 inhibition enhances venetoclax activity in vivo. (A) In vivo
dosing schedule. NSGS mice were injected with 1E6 MV4-11 cells and treated Q2D starting on
day 3 with 25 mg/kg venetoclax p.o. and/or 200 mg/kg Voruciclib p.o. (B) Average mouse body
weights for the treatment arms were measured on a daily basis. (C) Kaplan-Meier survival curve
between the treatment arms (Mantel-Cox statistical test).
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Next, we tested low-dose ara-C (palmO-ara-C derivative used in murine studies as ara-C
[cytarabine] is not tolerated in mice) in combination with venetoclax, with venetoclax given on a
daily basis and ara-C given every third day (Figure 4.16 A). Body weight loss for all treatment
groups was ≤ 8% (Figure 4.16 B). Median survival was 40 days for vehicle control and
venetoclax treated mice. Median survival of ara-C treated mice was 37.5 days, while combined
venetoclax and ara-C had a median survival of 43 days (7.5% ILS; Figure 4.16 C). Taken
together, our results demonstrate that CDK9 inhibition enhances the anti-leukemic activity of
venetoclax in vivo and the Q2D dosing schedule is effective both in vitro and in vivo.
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Figure 4.16. Cytarabine minimally enhances venetoclax activity in vivo. (A) In vivo dosing
schedule. NSGS mice were injected with 1E6 MV4-11 cells and treated Q2D starting on day 3
with 25 mg/kg venetoclax p.o. and/or 16 mg/kg/inj palmo-ara-C i.p. Q3D. (B) Average mouse
body weights for the treatment arms were measured on a daily basis. (C) Kaplan-Meier survival
curve between the treatment arms (Mantel-Cox statistical test).
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Patients

Gender Age
Disease
(year) status

FAB
subtype

Cytogenetics

Blast
purity
(%)

AML#196 Female

40

Newly
diagnosed

M5

46, XX

98.00

AML#198 Female

44

Newly
diagnosed

M2

46, XX,
t(8;21)(q22;q22)

68.00

AML#200 Male

44

M2

46, XY

77.00

AML#203 Female

13

M3

NA

NA

Newly
diagnosed
Newly
diagnosed

Gene
mutation
NPM-1,
FLT3-ITD,
DNMT3A
ASXL1, KRAS, NRAS
CEBPA dm,
FLT3-ITD
NA

PMLNewly
46, XX, t(15;17):
RARα,
AML#205 Female 61
M3
90.15
diagnosed
(q22;q21)
ATRX,
FLT3-ITD
DNMT3A,
Newly
AML#206 Male
36
M1
46, XY
90.50
IDH2,
diagnosed
NPM1
Table 4.1. Patient characteristics of primary AML patient samples. NA, not available

4.4 Discussion
In this chapter we confirmed the role of Mcl-1 downregulation by CDK9 inhibition to
enhance venetoclax-induced apoptosis in AML cells. Similar to findings in DLBCL, voruciclib
treatment was found to quickly downregulate Mcl-1 in AML (188). Also similar to their study,
voruciclib was found to synergize with venetoclax in AML. Flavopiridol was also found to
synergize with venetoclax in AML cells, matching previous findings in primary AML cells
(148). The combination treatment was found to be caspase dependent (Figure 4.11). However,
Bax/Bak knockdown did not fully rescue the cells from combination treatment. The Bax/Bak
knockdown may not have been sufficient as residual Bax and/or Bak may have been sufficient to
induce apoptosis. Alternatively, the extrinsic apoptotic may have been activated as
downregulation of c-Myc has been shown to increase TRAIL expression (193).
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In addition to the confirmed hypothesized mechanism of Mcl-1 downregulation by CDK9
inhibition synergizing with venetoclax in AML, we found previously unrecognized novel
mechanisms that will add to preclinical development as well as guide the use of CDK9 inhibitors
in the clinic. While other studies have shown that Mcl-1 plays a role in the anti-leukemic activity
of CDK9 inhibition in combination with venetoclax (148, 188, 194), we found that CDK9
inhibitor downregulation of Mcl-1 was transient (Figure 4.3&4.4) and that continuous CDK9
inhibition no longer reduced Mcl-1 protein nor enhanced venetoclax activity (Figure 4.14).
However, an intermittent schedule was found to resume downregulation of Mcl-1 and enhance
venetoclax activity. Further, a short intermittent administration schedule, e.g. every other day,
showed significant survival benefit for voruciclib in combination with venetoclax (Figure 4.15
C). Voruciclib in combination with venetoclax resulted in a 20.9% ILS, while low-dose ara-C in
combination with venetoclax only increased the lifespan by 7.5% (Figure 4.16). MV4-11 cells
are relatively resistant to ara-C in vitro (2 μM treatment for 24 h only results in 20% Annexin V
positive cells (141)). Thus, our data suggests that voruciclib in combination with venetoclax may
be a potential promising option for ara-C resistant AML cases.
Another novel finding was the role of c-Myc in the synergistic activity of voruciclib in
combination with venetoclax in AML. Mcl-1 overexpression only partially rescued AML cells
from venetoclax in combination with voruciclib treatment (Figure 4.8 B&D), indicating that
downregulation of Mcl-1 was only part of the mechanism of action of the combination treatment.
c-Myc inhibition significantly and greatly enhanced venetoclax activity (Figure 4.11 A-B),
especially when combined with the knockdown of Mcl-1 (Figure 4.12). These results suggest
that while downregulation of both c-Myc and Mcl-1 are important contributors to voruciclib’s
enhancement of venetoclax activity in AML cells, their effects alone in enhancing venetoclax
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activity are moderate. Further studies to determine how downregulation of c-Myc enhances
venetoclax activity are needed.
In summary, voruciclib synergizes with venetoclax in AML cells. Voruciclib treatment
results in downregulation of c-Myc and Mcl-1, which both contribute to venetoclax activity
(Figure 4.18). Voruciclib alone and in combination with venetoclax were observed as more
effective with an intermittent drug administration schedule in vitro and a Q2D schedule of
voruciclib was effective in vivo. Based on our study, continuous combination treatment shows
efficacy, though enhancement from downregulation of Mcl-1 is lost, suggesting that for optimal
results, an intermittent schedule should be considered. Such a schedule may reduce toxicity, as
time between treatments will likely be prolonged in order to account for Mcl-1 rebound. In
conclusion, our results support further clinical development of voruciclib in combination with
venetoclax for the treatment of AML and provide evidence to suggest that CDK9 inhibitors
should be administered with an intermittent schedule.
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Figure 4.18. Proposed mechanism by which voruciclib synergizes with venetoclax.
Venetoclax (VEN) treatment prevents Bim from binding to Bcl-2. In sensitive cells, there is an
inadequate amount of Mcl-1 to sequester all of the excess Bim, resulting in free Bim, which can
then activate the canonical intrinsic apoptosis pathway (black arrows). In venetoclax-resistant
cells, the Bim not bound to Bcl-2 is sequestered by Mcl-1, stabilizing Mcl-1, and ultimately
resulting in survival (blue arrows). CDK9 inhibition by voruciclib, reduces Mcl-1 protein levels
by decreasing transcription, leading to reduced sequestration of Bim by Mcl-1. Additional, prosurvival c-Myc is decreased by CDK9 inhibition (green arrows) and enhances venetoclax activity
by an unknown means. This, in combination with venetoclax, can free Bim to bind to Bak and/or
Bax, induce loss of mitochondrial membrane potential and induce apoptosis.
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CHAPTER 5: CONCLUSIONS AND FUTURE
DIRECTIONS
5.1 Significance
The goal of this dissertation project was to provide proof-of-concept strategies for
overcoming resistance to venetoclax in AML. Preliminary studies by our lab and others have
shown the efficacy and limitations of Bcl-2 inhibition in AML and other malignancies. In the
context of AML, Bcl-2 inhibition by venetoclax has good overall response rates and is well
tolerated but also has a high rate of relapse (82). Combination therapies (with azacitidine,
decititabine, or LDAC) proved to be slightly more effective than the standard of care for older
and chemotherapy unfit patients, leading to the approval of venetoclax for use in combination
therapies in late 2018 (79, 195). Our lab and others found that venetoclax-resistant AML cells
compensate the decreased binding of Bim to Bcl-2 with increased binding of Bim to Mcl-1,
preventing Bim from inducing apoptosis (86, 141). Due to the shallow, charged, hydrophobic,
and rigid nature of the Mcl-1 binding site, Mcl-1 inhibitors had remained elusive (charged and
hydrophobic molecules do not penetrate the cell well) (196).
In Chapter 2, we tested whether the recently developed Mcl-1-specific inhibitor, A1210477, could overcome resistance to venetoclax treatment (142, 143). The combination of
venetoclax and A-1210477 synergistically induced apoptosis in AML cell lines and primary
patient samples. A-1210477 was able to disrupt increased binding of Bim to Mcl-1 induced by
venetoclax. While A-1210477 has poor bioavailability and cell penetrance, it was still useful in
studying the mechanistic role of Mcl-1 inhibition in a proof-of-concept manner (197). At the
time, no other putative Mcl-1-specific small molecule inhibitors were available and even now,
Mcl-1 inhibitors are only just beginning to enter clinical trials (198, 199).
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In Chapter 3, we tested whether inhibition of XPO1, whose overexpression is associated
with poor prognosis and whose inhibition downregulates Mcl-1, could overcome resistance to
venetoclax treatment (145). KPT-330, also known as selinexor, inhibits XPO1, downregulates
Mcl-1, and preferentially targets leukemic initiating cells over normal hematopoietic stem cells
(180). KPT-330 was in phase I and II trials in multiple hematological and solid tumors at the
time of the Chapter 3 research and was approved in July 2019 for R/R MM (NCT02336815).
While KPT-330 decreased Mcl-1 protein levels through decreased Mcl-1 transcripts in CLL, we
found that KPT-330 decreased Mcl-1 protein stability but not transcript levels in AML. While,
Mcl-1 levels decreased after apoptosis induction, at apoptosis induction, Bim-Mcl-1 binding was
disrupted. Bim to Mcl-1 binding as well as protein stability can be altered by post-translational
modifications and may play a role in the mechanism of action of KPT-330 disruption of BimMcl-1 interaction, decrease in Mcl-1 stability, and synergy with venetoclax.
During the course of our studies, KPT-8602 (also known as eltanexor), was developed to
improve tolerability (reduced blood brain barrier penetration) and efficacy compared to KPT-330
(184). While the mechanism was less explored due to this late timing, we were able to confirm
similar effects as KPT-330: synergy with venetoclax in apoptosis induction and Mcl-1
downregulation. Overall, the combination of XPO1 and Bcl-2 inhibition is effective in AML.
Questions remain on Bim and Mcl-1 modifications and stability, in vivo efficacy and tolerability,
and selectivity versus normal cells.
Having shown that Mcl-1 can be downregulated through decreased protein stability to
synergize with venetoclax, in Chapter 4 we explored whether transcriptional downregulation of
Mcl-1 could have similar effects.

Mcl-1 is a short lived, transiently expressed protein.
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Transcriptional levels could affect Mcl-1 protein levels. Many stress response genes also turn on
Mcl-1 transcription as a survival mechanism to fix damage or overcome stresses (144).
CDK9, which is part of the positive transcription elongation factor complex b (pTEFb),
regulates transiently expressed pro-survival genes including but not limited to Mcl-1, Cyclin D1,
and c-Myc (186, 187, 200). Inhibition of CDK9 by the pan-CDK inhibitor flavopiridol (in phase
II trials in AML) can decrease Mcl-1 transcript levels, has anti-leukemic activity, and can
synergize with venetoclax in AML (148-150). There are concerns about the off target effects and
toxicity of flavopiridol. A second-generation CDK9-selective inhibitor voruciclib has greater
CDK9 selectivity than flavopiridol and in the diffuse large B cell lymphoma (DLBCL) model
synergized with venetoclax to kill lymphoma cells in vitro and in vivo. We found that voruciclib
synergizes with venetoclax in AML cell lines and primary patient samples and effective in vivo.
Several novel mechanisms were found including that c-Myc downregulation (not just Mcl-1
downregulation) by CDK9 inhibition contributed to the efficacy of the combination treatment.
Mcl-1 downregulation by CDK9 inhibition was found to be transient. Despite the treatment
effect on apoptosis being entirely caspase dependent, Bax/Bak knockdown did not fully rescue
the cells from treatment. A complete Bak/Bax knockout may rescue the cells or the extrinsic
pathway may be involved (201). Another novel finding was that repeated CDK9 inhibition was
found to be less effective than interrupted CDK9 inhibition, likely a result of transient
compensation of the cells in response to CDK9 inhibition. The interrupted schedule was found to
be effective in vivo. In summary, the results support the clinical development of combined CDK9
and Bcl-2 inhibition with an interrupted dosing scheduling that may improve efficacy while
reducing toxicity.
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In addition to venetoclax, which targets Bcl-2, 7 other drugs received FDA approval in
AML, with targets such as CD33, IDH1/2, FLT3, and SHH (Figure 1.2). AML is a well-studied
and characterized disease with targeted therapies finally coming to fruition. Despite these
advances, relapse and tolerability remain a concern. Single agent treatments run the risk of
selecting for a more resistant leukemic population (202). Our studies seek to target these difficult
to target cells using well-tolerated therapies that are clinically relevant in the hopes of
overcoming these challenges.

5.2 Future Directions
The insights provided by this dissertation and the field of Bcl-2 inhibition in AML, leave
many open questions. Venetoclax seems to enhance many chemotherapeutic agents through
reduced sequestration of pro-apoptotic Bim. While my dissertation studies outline the efficacy of
co-targeting Bcl-2 and Mcl-1 and the efficacy of targeting Mcl-1 through indirect means,
questions remain of the efficacy, selectivity, and mechanisms of these treatments.
The first major question that remains is how Mcl-1 stability and binding is affected by
our treatments. Venetoclax alone is known to increase Mcl-1 protein levels through increased
protein stability but not through increased Mcl-1 transcripts. This stabilization is also Bim
dependent. The BH3 binding site of Mcl-1 is used by E3 ligases (e.g. Mule, β-TrCP, FBW7,
Trim17, and SCFβ) to ubiquitinate Mcl-1 and promotes its degradation (203-205). A-1210477,
like Bim, occupies the BH3 binding pocket of Mcl-1, increasing Mcl-1 levels. It is possible that
competition for E3 ligases affects Mcl-1 protein stability. Deubiquitinases (e.g. USP9X and
USP28) or E3 ligase levels may be modulated as well.
Alternatively, XPO1 inhibition affects Bim-Mcl-1 binding followed by decreased Mcl-1
stability. Post-translational modifications can affect Bim-Mcl-1 binding as well as their binding
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to E3 ligases and deubiquitinases (206). Mcl-1 can be phosphorylated by many signaling
molecules (e.g. GSK3β, p38, JNK, ERK) which are known to affect protein stability (144).
During the course of my dissertation work, developments were made in the development
of small molecule inhibitors. Several Mcl-1 inhibitors (e.g. AMG176, AZD5991, VU661013,
and S64315) have reached phase I trials, although no data has been reported yet (198, 207, 208).
It remains to be seen in the clinic whether this on target activity improves upon more broad
acting nature of the inhibitors (e.g. pan CDK inhibition of CDK inhibitors, broad activity of
FLT3 inhibitors) (49, 188). This was shown in chapter 4, where CDK9 inhibition activity relied
on targeting both Mcl-1 and c-Myc. Additionally, the alternative roles of Mcl-1, such as in DNA
damage repair, oxidative phosphorylation regulation, and the UPR may contribute to single drug
and combination efficacy (104, 111, 112).
In addition to new therapies in preclinical and clinical development, much is to be
learned about recent drug approvals in AML. Half of the recent approvals were approved in
phase I and II trials (section 1.1.6) and the longer term efficacy and tolerability have yet to be
determined. In addition, most approvals were for cohorts of patients that failed or were unable to
tolerate other therapies (e.g. R/R AML, older than 75) with the exception of mylotarg (CD33+
AML) and midostaurin (FLT3 mutant AML). Future trials are focusing on the benefit of these
new drugs for a broader set of patients and/or in combination with other therapies, including
venetoclax (209, 210). Questions remain on which patients will benefit from these therapies and
potential patient selection to find patients who will benefit most from these therapies (211, 212).
A major caveat of in vitro and in vivo studies is their applicability to the clinic. In vitro
models generally lack cellular crosstalk found in the marrow stroma. Leukemic cells are known
to share mitochondria with stromal marrow cells to enhance their survival in addition to
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benefitting from supporting growth factors (213). In addition, most cell culture is performed at
21% O2 while the peripheral blood and marrow have much lower oxygen levels (214). Hypoxia
is known to affect stromal and hypoxia inducible factor (26) signaling which can drastically alter
drug efficacy (215, 216). Preclinical models are necessary for the timely and cost effective
testing of theories but ultimately the true test of a drug’s tolerability, selectivity, and efficacy is
in the clinic.
In summary, co-targeting of Mcl-1 is effective in overcoming resistance to venetoclax in
AML. The question remains open whether recently developed Mcl-1 inhibitors will be effective
in the clinic. Alternatively, many chemotherapeutic anti-leukemic agents can indirectly target
Mcl-1, which allows them to enhance venetoclax activity. Future studies in the regulation of
Mcl-1 and mechanisms of efficacy and resistance can guide the clinical development and use of
combination therapies to continue to improve patient outcomes.
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Cell Line

U937

THP-1

OCIAML3

MV4-11

MOLM13

CTS

Subtype

M5

M5

M4

M5

M5a

M1

Age/
Sex

37/M

1/M

57/M

10/M

20/M

13/F

Venetoclax
Sensitive?

No

No

No

Cytogenetics

Properties

n=63 (58-69) 3n xxy
-2, -4, -6, +7, -9, -20, -21,
+3mar
t(1;12)(q21;p13),
der(5)t(1;5)(p22;q35),
add(9)p(22),
t(10;11)(p14;q23), i(11q),
i(12p), add(16)(q22),
add(19)(q13)
4n, n=94 (88-96) xy/xxy
-y, +1, +3, +6, +6, -8, -13, -19,
-22, -22, +2 mar
add(1)(p11), del(1)(q42.2),
i(2q)
del(6)(p21)x2-4, i(7p),
der(9)t(9;11)(p22;q23)i(9)p(10
)x2,
der(11)t(9;11)(p22;q23)x2,
add(12)(q24)x1-2,
der(13)t(8;13)(p11;12),
add(?18), q(21)
n=48(45-50)<2n>X/XY
+1, +5, +8
der(1)t(1;18)(p11;q11), i(5p),
del(13)(q13q21),
dup(17)(q21q25)

1st continuous
monocytic cell line
p53 null
CALM-AF10 fusion
Diffuse histiocytic
lymphoma, from
refractory pleural
effusion

Yes

XY, +8, +18, +19, -21,
t(4;11)(q21;q23) [MLL-AF4]

Yes

n=51(48-52)<2n>XY
+8, +8, +8, +13
del(8)(p1,p2),
ins(11;9)(q23;p22p23)

Yes

n=46, XX
-17, +22
t(6;11)(q27;q23) [MLL-AF6],
mar1, mar2

Table A1. Cell lines used in the dissertation work. (217)

2nd oldest monocytic
cell line
p53 null
Mutant NRAS
P15INK4B and
P16INK4A deletions
RB1 rearrangement
Well differentiated
At relapse

NPM1c type A
DNMT3A R882C
Peripheral blood at
diagnosis
FLT3-ITD
heterozygous and only
constitutively
phosphorylated line
Monocytic at diagnosis
P15INK4B and
P16INK4A deletions,
MLL-AF9 fusion
FLT3-ITD (gene level
only); no FLT3
expression
Monocytic
MDS/RAEB to M5a
Peripheral blood postBMT
Myelocytic

Author

Papaemanuil

Tefferi

Gangat

Han Lin

Hussaini

Ruffalo

Ley

Lindsley

Lindsley

Lindsley

Chun Ha

Wang

Welch
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Year

2016

2017

2018

2016

2018

2015

2013

2014

2014

2014

2016

2016

2016

n

1540

179

300

112

187

274

200

93

101

101

60

95

54

Median Age

18–65

73

<70

43

NA

61

62

62

62

50

45

74

Genes

111

27

27

260

21

71

82

82

82

54

410

264

n

Total %

TET2

13%

25%

26%

10%

15%

14%

55
WGS/
WES
8%

20%

9%

14%

8%

10%

15%

3296

14.7%

ASXL1

5%

30%

27%

16%

21%

5%

3%

32%

3%

8%

10%

11%

3195

10.4%

3%

4%

3%

4%

349

3.4%

8%

2%

1%

6%

2163

2.5%

SMC1A
BCOR

2%

2%

DNMT3A

25%

10%

13%

15%

15%

21%

26%

19%

28%

27%

8%

17%

15%

3296

21.1%

IDH2

10%

6%

4%

12%

12%

8%

10%

11%

11%

17%

14%

12%

17%

3296

9.7%

TP53

7%

13%

12%

14%

8%

8%

15%

9%

23%

8%

5%

26%

3184

9.6%

EZH2

3%

4%

3%

3%

2%

9%

2%

3%

2%

2%

2902

3.1%

IDH1

7%

3%

3%

10%

8%

10%

11%

11%

17%

6%

4%

9%

3184

7.3%

10%

2%

4%

3%

2%

4%

2%

6%

2783

4.3%

15%

9%

10%

31%

11%

11%

5%

17%

3124

10.8%

8%

20%

1%

10%

4%

19%

2737

8.3%

3%

6%

4%

4%

1%

2%

2258

2.8%

3%

12%

7%

2376

5.7%

KIT

5%

2%

RUNX1

10%

11%

10%

SRSF2

6%

16%

13%

NF1

3%

WT1

5%

FLT3

37%

NPM1

29%

KRAS

5%

NRAS

19%

ZRSR2

1%

SF3B1

3%

STAG2

4%

U2AF1

2%

SETBP1
PTPN11

11%
1%

21%

4%

6%

11%

16%

28%

19%

28%

16%

32%

19%

6%

2996

27.5%

11%

16%

27%

5%

30%

16%

24%

22%

11%

2705

24.1%

4%

12%

8%

4%

11%

3%

4%

2458

5.8%

6%

12%

23%

8%

13%

2%

13%

9%

2705

15.4%

12%
10%
20%

30%

10%

16%
3%

10%
3%

1%

2%

0%

2035

2.0%

5%

11%

8%
1%

3%

2%

1%

7%

2984

7.3%

4%

14%

2%

6%

4%

5%

6%

2318

4.8%

6%

16%

4%

5%

7%

9%

2624

5.3%

4%

974

4.5%

10%

9%

5%
4%

SMC3

4%

2%

JAK2

1%

ETV6

1%

RAD21

4%

CBL

3%

PHF6

3%

U2AF2

0%

CEBPA

8%

1%

2%

5%

5%

9%

2%

4%

2%

2518

7.0%

2%

4%

2%

4%

2%

2%

778

2.4%

2%

1%

6%

2115

1.7%

2%

1%

4%

2210

2.3%

3%

2%

2318

3.4%

6%

2889

3.3%

7%

2544

3.7%

0%

1894

2.3%

4%

3296

7.3%

10%
10%

1%

3%

3%

2%
2%

2%

3%

4%

4%

10%

3%

5%

2%

4%

2%

10%

4%

3%

5%

10%

2%

6%

3%

1%

1%

14%
3%

3%

15%

7%

5%

6%

30%

Table A.2. AML mutation frequencies from multiple Next Gen Sequencing manuscripts.
This table was derived from “Next Gen Sequencing in AML” by Leisch et. Al. (30, 42) This
review tabulated the results of AML mutation frequencies from numerous NGS (next generation
sequencing) studies of varying properties. The rightmost column is the percentage of mutated
patients across the studies that tested for that mutation. Mutations under 2% were excluded to
save space on a single page. WGS is whole genome sequencing. WES is whole exome
sequencing.
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Year

Drug

Type

Target

Subpopulation

Mylotarg

Antibody-drug
conjugate

CD33

CD33+ AML

Enasidenib

Small molecule

IDH2

R/R AML w/ IDH2 mutation

Midostaurin

Small molecule

FLT3

FLT3 mutant AML

Vyxeos

Liposome w/ Ara-C and
DNR at 5:1

Gilteritnib

Small molecule

FLT3,
AXL

FLT3 mutant R/R AML

Glasdegib

Small molecule

SHH

75+ years old or inductive
chemotherapy ineligible

Ivosidnib

Small molecule

IDH1

R/R AML w/ IDH1 mutation

Venetoclax

Small molecule

Bcl-2

75+ years old or inductive
chemotherapy ineligible

2017

t-AML, AML-MRC

2018

Table A.3. Summary of recent FDA approvals in AML.
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Figure A.4. Life expectancy curves derived from the United States Social Security
Administration (SSA) actuarial life tables. The life expectancy for healthy adults in the US for
comparison to the poor survival of aged leukemic patients (218).
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Acute Myeloid Leukemia (AML) is a frustratingly difficult to treat disease (67% 5 year
survival for children and 24% for adults). The standard of care, similar to outcomes, has seen
few improvements over the last several decades. The Bcl-2 family, which controls cell survival
and apoptosis, is dysregulated in AML. Bcl-2, which is overexpressed in AML and associated
with chemoresistance, is a promising therapeutic target. The now FDA approved venetoclax
(ABT-199) is a BH3 mimetic that is able to bind to anti-apoptotic Bcl-2 and prevent it from
sequestering pro-apoptotic Bim. While overall response rates are promising, our lab and others
had found that resistance often occurs through anti-apoptotic Mcl-1 sequestering Bim and
preventing apoptosis.
In this dissertation, we used the molecular tool and Mcl-1 inhibitor A-1210477 and found
that inhibition of Mcl-1 can synergize with venetoclax to induce apoptosis in AML cells. To
inhibit Mcl-1 in a more clinically relevant manner, we sought to target Mcl-1 transcription or
protein stability using clinically available drugs. XPO1 is overexpressed in AML cells and its
inhibition decreases Mcl-1 levels and shows anti-leukemic activity. XPO1 inhibition by KPT330 (selinexor) or KPT-8602 (eltanexor) was able to synergistically enhance apoptosis induced

168
by venetoclax. XPO1 inhibition decreased Mcl-1 by decreasing protein half-life but not
transcript levels. XPO1 inhibition and venetoclax were able to disrupt Bim binding to both Bcl-2
and Mcl-1.
CDK9 inhibition transcriptionally decreases levels of Mcl-1 and c-Myc, and shows antileukemic activity. CDK9 inhibition by flavopiridol or voruciclib decreases Mcl-1 transcripts in a
transient manner. CDK9 inhibition was able to disrupt Bim binding to Mcl-1 alone and in
combination with venetoclax. The efficacy of the combination was dependent upon
downregulation of Mcl-1 and c-Myc. Interrupted dosing of CDK9 inhibition was effective in
vitro and in vivo.
Overall, Mcl-1 inhibition is a valid strategy to overcome resistance to venetoclax in
AML. This strategy has been validated through direct targeting of Mcl-1 and clinically relevant
indirect targeting of transcript levels or protein stability of Mcl-1 to decrease Mcl-1 protein
levels.
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